



Cite this: *Chem. Soc. Rev.*, 2023, 52, 3927

Received 6th March 2023

DOI: 10.1039/d3cs00167a

rsc.li/chem-soc-rev

## Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases

Vanessa J. Lee, Samuel E. Janisse and Marie C. Heffern \*

Transition metal dysregulation is associated with a host of pathologies, many of which are therapeutically targeted using chelators and ionophores. Chelators and ionophores are used as therapeutic metal-binding compounds which impart biological effects by sequestering or trafficking endogenous metal ions in an effort to restore homeostasis. Many current therapies take inspiration or derive directly from small molecules and peptides found in plants. This review focuses on plant-derived small molecule and peptide chelators and ionophores that can affect metabolic disease states. Understanding the coordination chemistry, bioavailability, and bioactivity of such molecules provides the tools to further research applications of plant-based chelators and ionophores.

### 1. Brief introduction to chelators and ionophores in therapy

Transition metals are pervasive in biology and are increasingly recognized for their essential biological activity beyond their traditional role as tightly bound structural cofactors. It has long been established that redox-active transition metals serve as static cofactors for an estimated one-third of all proteins as well as DNA and RNA.<sup>1</sup> Conversely, the main group alkali earth metals that are identified for participation in signaling

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA. E-mail: mcheffern@ucdavis.edu



**Vanessa J. Lee**

focuses on identifying natural products that interact with metal ions and understanding how those interactions may be effective in modulating metabolic disease states.

Vanessa Lee is a chemistry graduate student in the Heffern Lab at UC Davis. She performed undergraduate research developing methodologies for single-sided NMR instruments with Tyler Meldrum at The College of William and Mary where she obtained a degree in chemistry (BS). Upon entering graduate school at UC Davis, she began studying bioinorganic systems through an analytical chemistry lens. Her graduate research

pathways use labile metal pools.<sup>2</sup> Progressively however, transition metals (most notably copper, iron, zinc, and manganese) are being studied for their involvement in signaling pathways through labile pools.<sup>3</sup> The makeup of these populations remains elusive, but observed differences in labile transition metal pools is associated with a host of disease states.<sup>4–6</sup>

Due to their potential toxicity, transition metals are tightly regulated in biology. Dysregulation of transition metals is correlated with a wide range of pathologies including cancers, cardiovascular disease, neurodegenerative diseases, and metabolic diseases.<sup>7–12</sup> Metabolic diseases include inherited disorders, such as Wilson and Menkes diseases, and chronic conditions including diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). Some metabolic diseases, like Wilson



**Samuel E. Janisse**

Samuel Janisse is a graduate student in Chemistry in the Heffern lab. He obtained an undergraduate degree in biochemistry (BS) from George Fox University where he researched and synthesized far-red fluorescent probes for high-resolution live cell imaging. After graduating, he performed chemical extractions and low level residue analysis of plants, soil, and water for a high-output analytical testing lab. His graduate research focuses on developing analytical workflows to elucidate metal micronutrient dynamics and regulation in the extracellular space with an emphasis on discovering novel therapeutic targets and disease biomarkers.




Fig. 1 Chelators (purple arcs) are small molecules that can cross cell membranes, bind metal ions (represented by spheres; the different colors – blue and orange – convey the presence of different metal ions), and subsequently evacuate bound ions from the cell. Conversely, ionophores (green arcs) are small molecules that extracellularly bind metal ions and import them into the cell passing through the cell membrane.

and Menkes diseases, have clear connections to metal metabolism through mutations in metal trafficking proteins. Others, including NAFLD and metabolic syndrome, have no direct relationship to metal metabolism, but have been correlated with transition metal dysregulation<sup>7,12</sup> As such, treatments for these diseases include attempts to restore metal homeostasis through employment of chelators and ionophores (Fig. 1).

Chelation therapy is well-established in the treatment of Wilson disease and has gone through clinical trials for the treatment of cancer and Alzheimer's disease.<sup>7,13,14</sup> These treatments use chelators which are small molecules that selectively bind, sequester, and evacuate metal ions from the cell. Conversely, ionophores are small molecules that bind and import metal ions into the cell circumventing standard metal ion importers. While chelators and ionophores serve different purposes, they share necessary properties for metal trafficking.



Marie C. Heffern

Marie C. Heffern is an assistant professor of chemistry at the University of California, Davis, where she started in August 2017. She obtained a dual degree in Chemistry (BS) and Religion (BA) from the University of Southern California where she researched low-temperature synthetic routes to perovskite nanocrystals with Richard L. Brutcher. She earned her PhD at Northwestern University with Thomas J. Meade investigating metal complexes as protein inhibitors. Following her graduate studies, she trained with Christopher Chang at the University of California, Berkeley, researching *in vivo* imaging probes for redox-active metals. Her research group focuses on interdisciplinary approaches within the field of bioinorganic chemistry with a particular emphasis in metals in medicine. Specifically, the team is investigating the impact and applications of extracellular metals trafficking in metabolic diseases.

These properties include a low molecular weight, hydrophobicity that is sufficient for crossing cell membranes, and the ability to specifically bind metal ions.<sup>15–18</sup>

Medicinal chemistry has long taken inspiration from nature, with many drug candidates emulating small molecules and peptides found in plants.<sup>19</sup> Due to the association between many chronic metabolic diseases and diet, it is natural to look towards food sources in treatments of such diseases. This review will focus on plant-derived small molecules towards therapy for metabolic diseases. One of the common health benefits of plant products is antioxidant activity.<sup>20</sup> Classes of small molecules such as polyphenols and carotenoids have long been studied for radical scavenging activity and protection against oxidative stress. These small molecules often possess antioxidant activity through interactions with metal ions. Metal ions such as iron and copper perform Fenton or Fenton-like chemistry which is a source of reactive oxygen species (ROS).<sup>21,22</sup> ROS production is linked to metabolic regulation, and as such, perturbation in ROS production is associated with metabolic diseases. For detailed information on the pathways affected by ROS production in metabolic regulation, see the review by Forrester *et al.*<sup>23</sup> Oxidative damage induced by redox-active metals can be combatted by reduction or chelation of said metal ions. Thus, small molecules that can bind metal ions may reduce their reactivity and thereby reduce oxidative stress. However, some plant-based chelators and ionophores may offer their beneficial effect independent of their redox activity, but the mechanisms for such activity remain uncertain. The bioactivities discussed in this review are subdivided into structural categories of plant-based molecules in an effort to highlight molecular components that may be associated with function.

## 2. Background on metal dysregulation in metabolic diseases and therapeutic applications of metal binders

### 2.1 Hereditary diseases related to metal dysregulation

**2.1.1 Wilson disease.** Wilson disease (WD) is a hereditary disease affecting an estimated 1 in 30 000<sup>24</sup> people worldwide. WD involves a mutation in the ATPase copper transporting beta protein (ATP7B) resulting in the obliteration of the copper transporter's ability to export copper *via* the biliary excretion pathway and uncontrolled copper accumulation in several organs (Fig. 2).<sup>25</sup> The copper overload in patients with WD leads to deleterious neurological and hepatic outcomes, such as steatosis and cirrhosis.<sup>26–28</sup> While the exact mechanisms of liver damage in WD is unclear, the generation of excess oxidative stress due to the buildup of copper culminates in an increase in lipid peroxidation and hepatic dysfunction.<sup>29,30</sup> Moreover, the reduction in intracellular copper transport from the mutation in ATP7B prevents adequate copper loading into the ferroxidase ceruloplasmin as it matures through the trans-Golgi network.<sup>31</sup> This results in a drastic increase of apoceruloplasmin, or non-copper binding ceruloplasmin, relative to holoceruloplasmin which contains copper. Currently, the




Fig. 2 Hereditary diseases including Menkes and Wilson diseases are linked to mutations in copper-trafficking proteins. These mutations result in dysregulation of copper populations and subsequent detrimental symptoms. Chelates are clinically employed for management and treatment of these disease. Symptoms of metabolic disorders such as type 2 diabetes are alleviated by molecules known to have chelation or ionophoric properties (indicated with purple arcs), but their mechanisms of action require further investigation. While blue spheres represent copper centers and orange spheres represent iron centers in the figure, further mechanistic insight is required to determine chelator selectivity *in vivo* as well as the role and interaction metal-binding serum proteins (yellow blobs) may play in metal availability and ligand exchange.

diagnostic criteria for WD involves screening patients relying on serum ceruloplasmin and copper levels, which are often significantly lower and higher, respectively.<sup>27,28</sup> The increase in non-ceruloplasmin bound copper is believed to be a direct result of the release of copper from degrading hepatocytes.<sup>27,32</sup> Although damage can occur if copper imbalance is not remedied, if diagnosed early, WD can be managed.

Current treatments include zinc supplementation and copper chelator therapy. Zinc supplementation is believed to inhibit copper uptake in the gastrointestinal tract by inducing metallothionein production,<sup>33</sup> which in turn results in increased metallothionein-bound copper and subsequent excretion by intestinal sloughing.<sup>34</sup> While zinc supplementation has consistently been effective in WD maintenance, it has been suggested that it is not as effective as chelating therapies in preventing liver damage.<sup>35</sup> Chelation therapy for WD was first suggested in the early 1950's when researchers found that administering 2,3-dimer-captopropalol (also called BAL) led to a significant decrease in neurological symptoms observed in patients.<sup>36</sup> However, despite BAL showing a profound impact in increasing quality and length of life for patients with WD, it required regular invasive intramuscular injection, prompting the development more accessible treatments.<sup>37</sup>

The most common chelators used in current treatments of WD are D-penicillamine (DPA) and trientine (TETA), which are taken orally. DPA, first used as a therapeutic 1956,<sup>38</sup> contains three main functional groups: thiol, amine, and carboxylic acid. D-Penicillamine is reported to be a bidentate chelator binding copper(I) with the amine and thiol functional group and a tridentate chelator for copper(II) where the carboxylate is thought to participate.<sup>39</sup> Once binding to copper, the D-penicillamine-copper complex is excreted *via* the urine. While an improvement

to BAL, DPA has been associated with various disadvantageous side effects, such as gastrointestinal irritation, cytopenia, proteinuria, myasthenic syndrome, and degenerative dermopathy.<sup>40,41</sup> Triene is the other commonly administered copper chelator used to treat WD. TETA is a polyamine containing a total of four nitrogen groups with two primary amines and two additional secondary amines separated by two aliphatic carbons ( $-\text{CH}_2\text{CH}_2-$ ). The four nitrogen atoms coordinate copper resulting in a square planar complex. Similar to DPA, once copper is bound by TETA, it is excreted *via* the kidneys. Moreover, it has been shown to have efficacy in reducing copper absorption if taken prior to eating. However, despite TETA being distributed throughout various tissues post administration, the copper pool that TETA chelates is believed to be primarily in the blood whereas DPA can extract copper from tissues.<sup>42</sup>

**2.1.2 Menkes disease.** Menkes disease (MD), and the less severe occipital horn syndrome (OHS), is another hereditary disease involving the dysregulation of copper.<sup>43</sup> The X-linked genetic disorder involves the mutation of the copper transporter ATP7A, which regulates copper by utilizing ATP to transport copper across cell membranes. Classical MD is often lethal with an average life expectancy of less than three years<sup>44</sup> while those with OHS exhibit a longer lifespan. ATP7A is heavily involved in the transport of copper from the intestine after import by CTR1 and DMT1 into the blood where it is transported to the liver and other organs for utilization in various proteins. Mutations in ATP7A result in the aberrant transport of copper through the intestine resulting in low copper levels in serum, liver, and brain.<sup>45</sup> Diagnosis does not usually occur until the age of 3–6 months due to the appearance of hypopigmented hair that is prone to fraying, failure to thrive, vomiting, diarrhea, and loss consistent seizures. Later symptoms often include blindness,

respiratory failure, and vascular complications which ultimately lead to death.

Currently, the only treatment of MD and OHS is through the subcutaneous injection of copper histidine (CuHis), which is composed of copper coordinated by histidine in a 1:2 stoichiometric ratio. Early and sustained intervention with CuHis leads to an increase in life expectancy and has been shown to increase serum copper, CSF copper, and ceruloplasmin levels.<sup>46–48</sup> The mechanism of action has not been fully elucidated, however, the injection of CuHis complex into the subcutaneous tissues bypasses the gastrointestinal track and is introduced in the bloodstream. Once in the bloodstream, the copper can be chelated by the various copper chelating proteins, such as albumin, or exist as the CuHis complex.

## 2.2 Metabolic diseases with genetic and environmental contributions

**2.2.1 Type 2 diabetes, obesity, and metabolic syndrome.** Type 2 diabetes mellitus (T2D) is a rapidly expanding disease affecting millions of people worldwide. It is a metabolic disorder involving the dysregulation of lipid and glucose metabolism. The dysregulation has been directly linked to impaired insulin secretion by the pancreas and insulin resistance in peripheral tissues such as the liver and adipose.<sup>49,50</sup> Various factors have been associated with the onset of T2D including the dysregulation of metal micronutrients, such as iron, copper, and zinc.<sup>51,52</sup> In patients with T2D, there is a positive association between serum copper to zinc ratios and T2D as well as glycated hemoglobin.<sup>53</sup>

The association with iron and T2D has been observed in patients with hereditary hemostasis (HH) which is an iron disorder leading to iron accumulation in various tissues and increased serum ferritin.<sup>54,55</sup> However, there is a growing interest on the role of dietary iron and non-hereditary iron overload with T2D disease progression.<sup>56</sup> The use of iron chelators to treat iron overload has been well documented with various animal studies illustrating their utility. Early studies showed that obese (ob/ob lep<sup>-/-</sup>) mice were protected from deleterious effects of diabetes onset such as glucose intolerance and insulin resistance by the iron chelator FBS0701 administration.<sup>57</sup> Moreover, it was found that 15-day intraperitoneal administration of deferoxamine (DFO) led to decreased insulin resistance in adipose tissues of ob/ob mice.<sup>58</sup> The exact mechanism of these preventative outcomes have yet to be fully elucidated. One explanation is there is a reduction of oxidative stress associated with dysregulated iron levels that produce reactive oxygen species (ROS). The increase of ROS can lead to lipid peroxidation and advanced glycation end products.<sup>58–60</sup> There seems to be a link between iron chelation and preventing excess weight gain, which has been linked to a decrease in systemic oxidative stress. A recent study showed that mice who were fed a high fat diet supplemented with the iron chelator deferasirox (DFS) weighed less than the non-chelator high fat diet (HFD) controls, and obese mice on a HFD supplemented with DFS also experienced reduced weight gain compared to HFD ob/ob mice.<sup>61</sup>

Flavonoids have been linked to a decrease in T2D prevalence and obesity and are involved in glucose metabolism.

A cross-sectional study showed a strong negative association between daily quercetin intake and the prevalence of T2D<sup>62</sup> while another study showed that daily flavonoid intake led to a lower prevalence of diabetes and the inflammation marker – C-reactive protein.<sup>63</sup> Moreover, the daily intake of flavonoids was found to be inversely related to the prevalence of obesity. Administration of quercetin to Sprague–Dawley rats with streptozocin-induced diabetes showed improvements in hepatic glucose and lipid metabolism through increased Akt activity.<sup>64</sup> Studies conducted in skeletal muscle L6 myotubes showed that quercetin acts through the AMPK pathway in a manner similar to metformin,<sup>65</sup> as well as GLUT4 translocation to the membrane in mouse skeletal muscle.<sup>66</sup> A further link between the beneficial aspects of dietary quercetin and the reduction of ferroptosis, a mechanism in which lipid peroxidation catalyzed by iron leads to programmed cell death, was demonstrated in mouse pancreatic islets.<sup>67</sup> Interestingly, the authors also found that administration of DFO resulted in similar protective outcomes for ferroptosis induced by high glucose. This potentially suggests a mechanism where quercetin directly interacts with iron to prevent the generation of ROS, thereby protecting the cell from the onset of ferroptosis.

**2.2.2 Cancer.** Cancer is defined by a dysregulation of biochemical processes that govern proper cell homeostasis, leading to uncontrolled cell proliferation and resistance to cell death.<sup>68</sup> Aberrant metal micronutrient levels, such as copper levels, have been linked to various types of cancers.<sup>69–72</sup> Copper levels in the tumor microenvironment have been directly related to cancer cell proliferation and angiogenesis.<sup>73</sup> The mechanism of how such metals influence tumor progression and metastasis is relatively unexplored. However, recent research has elucidated copper trafficking through ATP7A, ATOX1, and LOX as a key pathway in breast cancer migration.<sup>74</sup> Furthermore, recent studies have elucidated copper as a key regulator of the autophagic kinases ULK1/2 through direct metal binding in lung adenocarcinoma.<sup>75</sup>

Due to the role of copper in cancer progression, there is growing interest in the application of copper depletion therapies for cancer treatments. Application of the copper chelator tetrathiomolybdate (TM) decreases the metastases of triple negative breast cancer to the lungs.<sup>76</sup> The exact mechanism of TM reducing cancer metastasis remains elusive, but recent research illustrates a link between the tumor microenvironment and collagen processing through the lysyl oxidase axis.<sup>77</sup> Additional research has revealed that TM mediates the inhibition of the mitochondrial Complex IV, which is involved in mitochondria energy production, *via* copper depletion.<sup>69</sup>

Beyond copper, the application the zinc chelator *N,N,N,N*-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN) to pancreatic cancer results in increased cell apoptosis and autophagy *in vitro*.<sup>78</sup> Iron chelation by deferasirox (DFX) inhibited the migration and reduced invasiveness of pancreatic cancer by reducing the activity of Rac1 and Cdc42, which are involved in a plethora of pro-cancer mechanisms such as tumor growth, migration, and angiogenesis.<sup>79</sup> This finding was significant as DFX can be given orally in contrast to DFO, which has been shown to decrease in tumor size in patients with hepatocellular carcinoma but requires intravenous application.<sup>80</sup> Beyond this

example, the potential role of iron chelation in affecting oncogenic pathways has been a wide topic of interest in the past few decades, and we refer the reader to extensive reviews and recent reports in this area.<sup>81–88</sup>

Anti-cancer properties of quercetin have been explored and show promise in reducing the severity of cancer. Mice given quercetin *via* oral gavage post tumor induction had a five-fold increase in life span compared to the vehicle.<sup>89</sup> The authors illustrated that quercetin intercalates with the DNA in cancer cells leading to S phase cell cycle arrest and subsequent apoptosis. Quercetin can also act by repressing expression of the receptor to advanced glycation end products (RAGE) leading to an increase in apoptosis and autophagy in pancreatic cells.<sup>90</sup>

### 3. Plant-derived with bioactivity related to transition metal interactions

#### 3.1 Phenolic compounds

Plants have been historically used for medicinal purposes predating modern science. As such, plant metabolites have been extensively studied for their potential biochemical activity, and many drug candidates resemble compounds found in nature. The most well-studied class of plant-derived compounds in applications of metabolic diseases are the phenolic compounds. Plant phenolic compounds, often referred to as polyphenols, are a class of small molecules that include molecules such as flavonoids, coumarins, and lignans. By definition, polyphenols are compounds that are composed of multiple phenolic rings. However, the term has been colloquially used to describe phenolic compounds including diphenols like catechol. To read more about the history and definition of the term polyphenols, you can read a review by Quideau *et al.*<sup>91</sup>

Polyphenols are secondary metabolites from fruits and vegetables and serve a variety of purposes in plants including aroma and color. Polyphenols are found in all plant products we consume and are often the source of the health benefits advertised for various herbs, fruits, and vegetables. Most plant polyphenols exist as conjugated forms (glycosides, esters, and amides) rather than in their free forms. The seemingly endless identification of novel plant phenols broaches the variety of roles they play in plant biology. Plant phenols are involved in activities ranging from protective effects (against predators or radiation) to reproduction to signaling.<sup>91</sup> The vast range of plant phenols necessitates categorization. Each subgroup of plant polyphenols shares a core structure and has a wide range of substitutions on the ring structure (Fig. 3). Of the subgroups of plant polyphenols, flavonoids are the most prevalently studied.


**3.1.1 Flavonoids.** Over 8000 molecules comprise the largest group of plant polyphenols, flavonoids. Flavonoids all share a core structure consisting of three rings: two phenyl rings (A and B) joined by a heterocyclic pyran ring (C). Subclasses of flavonoids are defined by substitution on and oxidation of the heterocyclic C-ring. There are subclasses of flavonoids: flavanols, flavanones, flavonols, flavones, anthocyanins, isoflavones, and chalcones. Flavonoids, which are found in all parts

of plants, are most often isolated *via* extraction from their natural sources.<sup>91</sup> Extraction is most commonly performed *via* a mixture of organic and aqueous solvents, though more current methods are continually being optimized.<sup>92</sup> Flavonoids have historic medicinal purposes, and modern techniques have been used to elucidate the bioactivity of flavonoids in diseases ranging from cancer to cardiovascular disease to metabolic diseases.<sup>93–96</sup> In particular, extensive research, including mechanistic and detailed structure-activity relationship studies, has ushered in important developments, understanding, and applications of flavonoid/metal interactions in neurodegenerative disorders.<sup>2,97–102</sup>

Flavonoids have been used in the treatment of diabetes, non-alcoholic fatty liver disease (NAFLD), and hyperlipidemia.<sup>94,103,104</sup> Yi *et al.* highlight the advances of the flavonol quercetin in clinical trials for treatment of metabolic diseases.<sup>103</sup> Quercetin has entered clinical trials in the treatment of type 2 diabetes mellitus (T2DM), hyperlipidemia, hypercholesterolemia, and NAFLD. The results from these clinical trials support the use of quercetin for increasing insulin secretion and improving insulin resistance, regulating glucose homeostasis, and reducing oxidative stress. Like quercetin, the flavonol (–)epicatechin, shows beneficial effects in the treatment of NAFLD-related symptoms.<sup>105</sup> In all of these applications, flavonoids are known to exhibit antioxidant and anti-inflammatory activity.<sup>95,106</sup>

The exact mechanisms of flavonoid antioxidant activity continue to be explored. It is understood that one path by which flavonoids prevent oxidative damage is by interacting with reactive metal species including iron and copper ions.<sup>107–110</sup> Flavonoid-metal complexes exhibit different behaviors than flavonoids alone.<sup>111,112</sup> Flavonoids have experimentally been shown to bind and reduce metal ions.<sup>110,113,114</sup> Samsonowicz *et al.* identify three main interaction sites on the flavonoid core structure at the B-ring 3',4'-dihydroxy group, the C-ring 3-hydroxy or 5-hydroxy group, and the C-ring 4-carbonyl group.<sup>115</sup> These interaction sites have been supported both experimentally and computationally.<sup>108,116</sup> Karlíčková *et al.* found that isoflavones containing a 5-hydroxy-4-keto substitution pattern were able to chelate ferric, ferrous, and cupric ions. The presence of a free 4'-hydroxyl group and the absence of a 5-hydroxyl group corresponded to redox activity in reducing Cu(II) ions.<sup>117</sup> However, many studies of flavonoid-metal complexes are contradictory in their characterization.<sup>115</sup> Binding affinities, binding ratios, and binding locations are all dynamic under varying experimental conditions. Further investigation of the effects of experimental conditions is warranted, but it is clear that flavonoid-metal interactions contribute to their antioxidant activity.<sup>118</sup>

Conversely, interactions between flavonoids and metal ions have also been implicated in pro-oxidant activity which contributes to observed anticancer and apoptogenic activity.<sup>119</sup> Similar to chelation ability, pro-oxidant interactions of flavonoids with metal ions are structure-dependent. The number of adjacent hydroxy groups and conjugation throughout the molecule affects prooxidant activity.<sup>95</sup> The distinction between anti- and pro-oxidant interactions between flavonoids and metal ions is slight



**Fig. 3** Phenolic plant compounds are known to affect biological functions associated with metabolic disease states. Additionally these phenolic compounds interact with d-block metal ions, but little is known about the intersection with effects on metabolic disease states.

and must be considered when thinking about these complexes in therapeutic contexts.

**3.1.2 Phenolic acids.** Phenolic acids contain a carboxylic acid and are the most produced phenolic compounds by plants. Plant phenolic acids are most abundant in the seeds, leaves, and skins of fruits.<sup>120</sup> There are two main groups that comprise plant phenolic acids: hydroxybenzoic and hydroxycinnamic acids.<sup>121</sup> Some of the more abundant hydroxybenzoic acids including syringic, vanillic, and protocatechuic acids exhibit many of the beneficial health effects previously discussed.

Hydroxybenzoic acids have been demonstrated to possess protective effects against a host of diseases including cancer, cardiovascular disease, and diabetes.<sup>122–125</sup> Of particular interest to metabolic diseases, Chang *et al.* found that vanillic acid has protective effects against hyperinsulinemia, hyperglycemia, and hyperlipidemia in a study with HFD fed rats.<sup>126</sup> Treating HFD rats with vanillic acid decreased blood glucose levels and increased expression of proteins associated with insulin signaling and lipid metabolism. Sreelekshmi *et al.* identify activation of glucokinase and reduction of lipid peroxidation by vanillic acid under hyperinsulinemic conditions in HepG2 cells.<sup>127,128</sup> Similarly, syringic acid protects against fat accumulation in the

liver of albino rats treated with acetaminophen as reported by Ramachandran *et al.*<sup>129</sup> Protocatechuic acid can also affect lipid and glucose metabolism in NAFLD conditions and ameliorate insulin resistance associated with diabetes.<sup>130,131</sup> The biological pathways affected by hydroxybenzoic acids continue to be investigated, but acids such as protocatechuic acid is known to activate mitogen-activated protein kinases (MAPKs) which are involved in inflammatory responses.<sup>123</sup>

Commonly encountered hydroxycinnamic acids including chlorogenic, ferulic, caffeic, and sinapic acids share biological properties to their hydroxybenzoic counterparts. Notably, ferulic acid derived from cereals demonstrates anti-hypertensive effects which may be attributed in part to its antioxidant activity.<sup>132,133</sup> Additionally, in obese mice and high-fat fed rats, caffeic acid and sinapic acid, respectively, modulate the gut microbiome to produce fewer microbiota associated with disease and inflammation.<sup>134,135</sup> Associated with metabolic disease, chlorogenic acid has been extensively studied *in vivo* and in clinical studies for its role as a nutraceutical against metabolic syndrome and related diseases including obesity, diabetes, and hypertension.<sup>136</sup> Shi *et al.* found that treatment of NAFLD mice with chlorogenic acid leads to decreased activation of

inflammatory cytokines (TNF- $\alpha$  and IL-6), reduced fasting blood glucose levels and blood lipids, and reduced insulin resistance.<sup>137</sup> This work is supported by observations that the improved conditions of HFD mice treated with chlorogenic acid was related to changes in mRNA levels of genes involved in glucose metabolism like GYS2, PCK, GK, and PFKL.<sup>138</sup> The same effects of chlorogenic acid were observed in human patients with NAFLD or T2D and exhibited similar results with improved metabolic readings.<sup>139</sup>

Unsurprisingly, phenolic acids are known to interact with transition metal ions through their carboxylic acid and phenol moieties.<sup>140–143</sup> Truong *et al.* used a density functional theory (DFT) approach to study the antioxidant *versus* pro-oxidant effects of ferulic acid interactions with iron ions at the carboxyl group.<sup>141</sup> Antioxidant activities of ferulic acid are more prominent than pro-oxidative reduction of Fe(III) except under specific conditions such as high concentrations of ferulic acid. Mazzone also employed DFT to study the interactions of Fe(II) with caffeic acid.<sup>144</sup> Using DFT coupled with experimental UV-Vis data, the binding site of caffeic acid with Fe(II) was identified as the carboxyl group, and caffeic acid–Fe(II) complex formation was found to be more energetically favorable than the production of H<sub>2</sub>O<sub>2</sub> through Fenton chemistry. Oke *et al.* studied the activity of a vanillic acid–Zn(II) complex under hyperglycemic conditions.<sup>145</sup> Similar to previous studies, the anti-oxidant activity was highlighted as a key mechanism of bioactivity. Another plant-derived carboxylic acid, nicotianamine (NA), was shown to aid in Fe(II) import facilitated by the proton-coupled amino acid transporter SLC36A1 (PAT1).<sup>146</sup> NA is a small organic molecule that can be obtained through consumption of fruits, vegetables, and legumes. Murata *et al.* use <sup>59</sup>Fe(II) to track iron import in Caco-2 cells by NA. Intracellular Fe(II) levels track with the concentration of NA–Fe(II) treatment, and the complex should be explored for use in iron deficiency treatments. While these studies explain a mechanism of antioxidant activity, there remains room to explore the interplay between metal chelation and protective effects against metabolic diseases of plant phenolic acids.

**3.1.3 Coumarins.** Coumarins have a benzopyrone core and are found in all parts of plants though they are concentrated in fruits.<sup>147</sup> Like the other phenolic compounds previously mentioned, coumarins are used to treat a range of pathologies including cancer, depression, and Alzheimer's Disease.<sup>148–151</sup> A thorough review by Hussain *et al.* discusses the biological and pharmaceutical properties of coumarins and their derivatives.<sup>147</sup> Some highlights pertinent to our topic include a study by Ali *et al.* where methanol extracts of *Angelica decursiva* exhibited inhibitory activity of protein tyrosine phosphatase 1B (PTP1B) and  $\alpha$ -glucosidase.<sup>152</sup> Correspondingly, Islam *et al.* also found PTP1B and  $\alpha$ -glucosidase inhibitory activity of coumarins extracted from *Artemisia capillaris*.<sup>153</sup> As their involvement in diabetes is understood, PTP1B and  $\alpha$ -glucosidase are targets for the treatment of diabetes, and thus coumarins which inhibit the activity of these enzymes possess therapeutic potential.<sup>154,155</sup> In animal models, coumarins and their derivatives exhibit protective effects against diabetes and associated renal damage.<sup>156,157</sup> Kang *et al.* administered esculin, a coumarin derivative, to streptozotocin-induced

diabetic mice and found that esculin combatted diabetes-associated symptoms including elevated blood glucose levels and increased hepatic glucose-6-phosphatase expression.<sup>156</sup> Non-obese diabetic mice were administered total coumarins extracted from *Urtica dentata*, and Wang *et al.* found that the treated mice showed decreased expression of the TLR4 gene which is involved in inflammation in type 1 diabetes.<sup>157</sup>

Coumarins are shown to interact with transition metal ions such as iron and copper.<sup>158–160</sup> García-Beltrán *et al.* synthesized a fluorescent probe sensitive to Cu(II) based on 3-amino-7-hydroxycoumarin.<sup>159</sup> While the proposed mechanism of the probe is through hydrolysis of an imine bond, Mergu *et al.* also designed a Cu(II)-sensitive probe which employs a coumarin moiety through which the copper ion is chelated.<sup>158</sup> Mladěnka *et al.* investigated the interactions of coumarins with iron ions *in vitro*.<sup>160</sup> At neutral pH, *ortho*-dihydroxy derivatives of coumarins, specifically 7,8-dihydroxy-4-methylcoumarin, were able to tightly bind ferrous ions. However, at acidic pH, the same *ortho*-dihydroxycoumarins demonstrated potential pro-oxidant activity through reduction of ferric ions. While the groundwork for coumarin–metal interactions exists, there remains room to investigate the relationship between coumarins, metals, and the protective effects of coumarins against metabolic diseases.

**3.1.4 Stilbenes.** With a core of 1,2-diphenylethylene, stilbenes are found as either *trans*- or *cis*-isomers.<sup>161</sup> The most known stilbene is resveratrol which is found in edible fruits and seeds such as grapes, pistachios, and berries.<sup>161</sup> Over 250 clinical trials have indicated health benefits of the *trans*-form of resveratrol in addressing cardiovascular diseases, neurological diseases, and metabolic diseases like diabetes.<sup>162</sup> Singh *et al.* present a summary of clinical trial data of resveratrol in their review article.<sup>162</sup> Some other notable bioactive stilbenes include oxyresveratrol, piceatannol, and pterostilbene.<sup>163</sup> These stilbenes too possess bioactivities such as anticancer and anti-hypertensive effects.<sup>164–166</sup> In the context of metabolic disease, Choi *et al.* reported that oxyresveratrol combatted metabolic dysregulation in high-fat diet-fed mice by increasing the expression of proteins including AMP-activated protein kinase  $\alpha$ , insulin receptor substrate 1, and insulin-dependent glucose transporter type 4 which are involved in lipid and glucose homeostasis.<sup>167</sup> Two studies by Choi *et al.* and Pan *et al.* note the increase of energy expenditure in high-fat diet-fed mice administered oxyresveratrol.<sup>168,169</sup> Both groups identify increasing expression of uncoupling protein 1 (UCP1), a mitochondrial membrane protein in brown adipose tissue, as a mechanism of induced thermogenesis by oxyresveratrol. Piceatannol exhibits anti-inflammatory and antioxidant activity in a variety of cell types and *in vivo* studies.<sup>170</sup> Kitada *et al.* studied the effects of piceatannol from *Passiflora edulis* on metabolic health in humans.<sup>171</sup> The preliminary results presented indicate that piceatannol increases insulin sensitivity and decreases blood pressure and heart rate. Similarly, pterostilbene reduces adiposity in white adipose tissue at a higher efficacy than resveratrol.<sup>172</sup> Resveratrol, though being the most-studied stilbene, has low oral bioavailability which supports the study of other stilbenes as potential therapeutics.<sup>173</sup>

Stilbenes interact with metal ions, and their complexes have demonstrated biological activity. Stilbene-copper complexes have been studied for their antitumor activity.<sup>174,175</sup> Resveratrol-Cu(II) and piceatannol-Cu(II) complexes induce apoptosis through production of ROS and DNA damage.<sup>175-177</sup> Tamboli *et al.* use electrospray ionization mass spectrometry (ESI-MS) paired with DFT calculations to understand the mechanisms by which resveratrol interacts with copper.<sup>178</sup> While the previously discussed phenolic compounds interact with metal ions mainly through oxygen-containing groups, resveratrol interacts with copper through its aromatic carbon atoms and alkenyl group. Though resveratrol does exhibit some copper chelating activity, Granzotto *et al.* suggest that resveratrol poses more of a risk of producing ROS than chelating copper.<sup>179</sup> Metal-interactions with resveratrol have been studied computationally<sup>180</sup> *in vitro*, but the exact mechanisms of interaction *in vivo* remain elusive. Majewski *et al.* studied the effects of resveratrol on copper deficient Wistar rats and found resveratrol to increase copper and zinc levels as well as superoxide dismutase (SOD) and ferric reducing antioxidant power (FRAP) which are related to antioxidant activity. While the clinical relevance of stilbenes is well-established in diseases associated with metal dyshomeostasis, the direct effects of stilbene-metal interactions on pathological states remains largely unexplored.

**3.1.5 Lignans.** In plants, lignans serve as structural compounds in the formation of lignin in the cell wall.<sup>181</sup> Lignans have a 2,3-dibenzylbutane structure and are consumed in fibrous foods like grains and legumes.<sup>182</sup> Though relatively low-abundant, lignans, as with other plant phenolic compounds, exhibit a range of biological activity from anti-cancer activity,<sup>182</sup> to gut microbiota modulation<sup>183</sup> to cholesterol reduction.<sup>184</sup> Lignans are consumed largely through cereals in western diets and are known to affect metabolic systems through nuclear receptors (NRs), particularly estrogen receptors (ERs).<sup>185</sup> Zanella *et al.* highlight the relationship between plant lignans and metabolic syndrome (MetS). Epidemiological studies show an inverse correlation between lignan intake and incidence of T2D, dyslipidemia, and fasting insulin serum levels. Additionally, the structural similarity of lignans to steroid hormones such as estrogen can play a role in modulation of hormone-related tumors by lignans.<sup>186</sup> Lignans including pinoresinol, sauchinone, sesamin, and honokiol can combat hepatic oxidative stress which is often associated with metabolic diseases.<sup>187-192</sup> Mice with liver injury induced by CCl<sub>4</sub> or *tert*-butyl hydroperoxide were treated with lignans which activated pathways including AMPK, JNK, SIRT3, and Nrf2/ARE. Due to their potent antioxidant activity, it is no surprise that lignans can bind metal ions.

Lignans have known interactions with metal ions, particularly iron. Donoso-Fierro *et al.* extracted, isolated, and studied the iron-binding abilities of lignans from *F. cupressoides* and *A. chilensis*.<sup>193</sup> Five lignans with iron-binding capacity of over 87% were identified as isolariciresinol, isotaxiresinol, matairesinol, methylmatairesinol, secoisolariciresinol, and didemethylmatairesinol. This work was followed up by Fucassi *et al.* who focused on secoisolariciresinol digucoside (SDG) and found that SDG was able to bind calcium, copper, lead, nickel, iron, and silver ions.<sup>194</sup>

While some of these metals are implicated in metabolic diseases affected by lignans, the direct connections between metal chelation, lignan intake, and instance of metabolic disease remain largely unexplored.

**3.1.6 Curcuminoids.** Curcuminoids are found in the rhizome of turmeric and have gained attention for their bioactivity.<sup>195</sup> The most common curcuminoid, curcumin, is a yellow polyphenolic pigment that contains two ferulic acid residues bridged by a seven-carbon methylene group. Clinical trials implicate curcumin in treatment for a range of disease states from rheumatoid arthritis to inflammatory bowel disease to Alzheimer's disease. Reviews by Pivari *et al.* and Zheng *et al.* highlight current understanding of treatment of diabetes with curcumin.<sup>195,196</sup> Yuan *et al.* performed meta-analysis of the effects of curcuminoids on blood lipids in adults with metabolic diseases.<sup>197</sup> While the results are preliminary, consumption of curcuminoids correlated with decreased levels of triglycerides, total cholesterol, and LDL and an increase in HDL. Newer work by Ibrahim *et al.* demonstrates hepatoprotective effects of curcuminoids.<sup>198</sup> Hepatic damage was induced in Wistar rats by administration of CCl<sub>4</sub>, and curcuminoids were administered in doses of 75, 150, and 300 mg. Liver enzyme levels (alanine transaminase, aspartate transaminase, and alkaline phosphatase) increase with liver damage caused by CCl<sub>4</sub> but are restored upon treatment with curcuminoids.

Expectedly, curcuminoids exhibit antioxidant activity and interact with metal ions. Pitchumani Violet Mary *et al.* used DFT in gas and DMSO solvent phases to study interactions of curcumin with Mn(II), Fe(II), and Zn(II).<sup>199</sup> Curcumin-Zn(II) complexes are the most stable of the three, though DMSO solvent interactions destabilize the complex. The binding site is identified as the diketone moiety, and metal complexes show increased antioxidant activity as compared to free curcumin. These calculations are supported by experimental results by Hieu *et al.*<sup>200</sup> Curcumin complexes with Fe(III), Ca(II), and Zn(II) were assessed for their solubility and antioxidant activity. Increased solubility of the metal complexes as compared to free curcumin correlated with increased antioxidant activity as assessed by the DPPH assay. A review by Prasad *et al.* summarizes the increased pharmacological activity of curcumin when complexed with metal ions.<sup>201</sup> Curcumin-metal complexes modulate a host of biomarkers involved in metabolic diseases including inflammatory cytokines IL-6, TNF- $\alpha$ , and NF- $\kappa$ B. Yuan *et al.* exploit the anti-inflammatory effects of curcumin-metal complexes in their Fe-Curcumin nanozyme employed for ROS scavenging and anti-inflammatory activity.<sup>202</sup> The strong chelating behavior of curcumin paired with its therapeutic effects requires further investigation for modulation of metal populations in metabolic disease states.

### 3.2 Carotenoids

Over 700 compounds comprise the group of natural pigments called carotenoids which impart yellow, red, and orange colors.<sup>203</sup> In plants, carotenoids serve roles in photosynthesis and in protection against oxidative damage.<sup>204</sup> Carotenoids, like the previously discussed compounds found in plants, have been studied for their potential use in therapeutics for pathologies

including cardiovascular disease and various cancers.<sup>205</sup> Another key role of carotenoids in human health is as a precursor for vitamin A and antioxidants which implicates their protective activity against oxidative damage.<sup>204</sup>

A study by Christensen *et al.* of 2003–2014 National Health and Nutrition Examination Survey (NHANES) data showed that increased intake and serum levels of carotenoids correlates with decreased instance of NAFLD.<sup>206</sup> Specifically,  $\alpha$ -carotene,  $\beta$ -carotene,  $\beta$ -cryptoxanthin, and lutein/zeaxanthin show strong associations with decreased risk of NAFLD which was assessed using ultrasonography.<sup>207</sup> While a healthy diet may largely affect the risk of disease onset, Christensen *et al.* show that including the healthy eating index of 2015 in their analysis did not eliminate the inverse relationship between increased serum carotenoid levels and risk of fatty liver disease.<sup>206</sup> As such, carotenoids exhibit therapeutic effects towards fatty liver diseases through an unclear mechanism of action. Elvira-Torales *et al.* highlight some mechanisms by which carotenoids impart their protective effects against liver damage through reduction of oxidative damage and modulation of genes associated with lipid metabolism.<sup>208</sup> Researchers note that levels of inflammatory cytokines including *TNF- $\alpha$* , *IL-6*, and *MCP-1* are repressed upon oral administration of carotenoids, specifically  $\beta$ -cryptoxanthin.<sup>208,209</sup> These cytokines likewise play a role in diabetes mellitus which is a chronic inflammatory disease. Expectedly, carotenoids present anti-diabetic properties as presented in a review by Roohbakhsh *et al.*<sup>210</sup> Researchers highlight that carotenoids reduce insulin resistance by affecting JNK, IKK $\beta$ , and PPAR $\gamma$ . JNK and IKK $\beta$  regulate phosphorylation of insulin receptor substrates, specifically IRS-1; PPAR $\gamma$  assists in metabolism of carbohydrates and decreases inflammation in the cell.

Unlike many of the previously mentioned plant-derived compounds, carotenoids have not been studied for chelation-based interactions with metal ions. Due to their lipophilic nature, the context under which carotenoid-metal ion interactions are studied is in reference to lipid oxidation.<sup>211</sup> Interactions between carotenoids and redox-active metals may contribute to their pro-oxidant activity by producing carotenoid radical cations through electron-transfer.

### 3.3 Peptides

Another group of plant-derived compounds that is of interest to human health is peptides. Peptide sequences within plant proteins are increasingly being recognized for their potential bioactivity and use as nutraceuticals.<sup>212</sup>

Many bioactive peptides are hydrolysis products of plant proteins where the proteins themselves do not present the same bioactivity. The hydrolysis products naturally occur through consumption by digestive enzymes such as trypsin and pepsin.<sup>212</sup> A typical workflow for preparation of plant-protein derived bioactive peptides involves hydrolysis of proteins through one of three methods: gastrointestinal digestion, enzymatic hydrolysis, or fermentation.<sup>213</sup> Enzymatic hydrolysis is the most common method and has been performed with a wide variety of enzymes derived from plants and microbes (Fig. 4).<sup>214</sup> The proteolytic enzyme selected for digestion affects the potential bioactivity of the resulting peptides because of the varied cleavage sites.<sup>214</sup>




Fig. 4 Subjecting plant-derived proteins to enzymatic hydrolysis generates bioactive peptides. Such peptides have been found to have metal-interacting properties with potential health benefits.

Hydrolysates from a range of foods consumed through diet have been studied for their bioactivity. Similar to their phenolic compound counterparts, plant protein hydrolysates are known to possess biological properties including anti-cancer, anti-inflammatory, and cardiovascular effects.<sup>215–222</sup> Within the realm of metabolic disease, peptides from plant protein hydrolysates have exhibited anti-diabetic, anti-obesity, and anti-oxidant activity.<sup>223,224</sup> Jakubczyl *et al.* highlight specific peptide sequences that demonstrate bioactivity towards ameliorating metabolic syndrome in their review.<sup>223</sup> Other recent reviews highlight therapeutic effects of plant-derived peptides towards diabetes and related complications.<sup>224,225</sup>

There are known metal-binding amino acid residues, thus it is expected that plant protein-derived peptides have metal-binding capacity.<sup>226</sup> Esfandi *et al.* hydrolyzed oat bran proteins using four proteases, Alcalase, Flavourzyme, papain, and Protamex.<sup>227</sup> Anti-oxidant assays and iron-chelating assays support the varied bioactivity of peptides produced by different proteases, with papain-hydrolyzed peptides having the highest iron-chelating activity. Hu *et al.* further investigated iron chelation by oat bran protein hydrolysates prepared with papain, ficin, and bromelian, separating peptides by size.<sup>228</sup> Larger peptides ( $>10$  kDa) hydrolyzed by papain have higher iron-chelating capacity than those produced by ficin and bromelian whereas small peptides ( $<1$  kDa) hydrolyzed by ficin have higher iron-chelating capacity than those produced by papain and bromelian. Kubglomsong *et al.* studied rice bran albumin hydrolysates from papain hydrolysis for their copper-chelating activity.<sup>229</sup> Using gradient elution by HPLC, the more hydrophilic peptides demonstrated the highest copper-chelating activity. Identification of the peptides from the strongest chelating fraction showed characteristic moieties such as sulfur-containing amino acids, repeating serine residues, tryptophan, and arginine. Similar to the plant phenolic compounds, the interplay between plant peptides, metal ions, and metabolic disease has much room to be explored.

## 4. Metal complexes of plant-based molecules as potential therapeutics for metabolic diseases

Current therapeutic design targeting metal dysregulation focuses largely on metal-trafficking small molecules.<sup>14,15</sup> Such molecules can act as metal chelators or metal ionophores.

Chelators sequester metal ions from the intracellular space and evacuate them out of the cell; ionophores bind metal ions in the extracellular space and traffic them into the cell across the cell membrane. Physicochemical requirements of small molecule chelators and ionophores include a moderate binding affinity to specific metal ions, sufficient lipophilicity to penetrate the cell membrane, and adequate complex stability.<sup>14</sup> Plant-derived compounds deserve to be considered for their therapeutic potential as metal chelators and ionophores. With known metal ion interactions, a range of binding affinities and lipophilicities, and varying complex stabilities, plant-derived small molecule-metal complexes possess the chemical properties to traffic metal ions. Indeed, small molecules like flavonoids have been studied in these contexts.

Flavonoids are known to interact with redox active metals such as copper and iron which are implicated in metabolic disease states such as diabetes, Wilson and Menkes disease, and metabolic syndrome. To date, much of the research regarding flavonoid-metal interactions focuses on their antioxidant activity. A review by Selvaraj *et al.* highlights the potential of flavonoid-metal complexes as therapeutics mainly for antioxidant and anti-inflammatory activity.<sup>230</sup> However, flavonoids are good candidates to study for their potential chelator or ionophore activity. Dai *et al.* present their study on flavones as Cu(II) ionophores.<sup>231</sup> Researchers highlight 3-hydroxyflavone as being the most effective copper ionophore. Using human hepatocytes, HepG2 cells, as a model system, 3-hydroxyflavone is shown to import copper into the cell at up to a 150-fold change. While the experimental conditions induce cell death due to cuproptosis,<sup>232</sup> the ionophore activity of 3-hydroxyflavone can be harnessed to address diseases under which intracellular copper levels are decreased. Further studies of flavonoid-metal interactions by our lab, show that flavonoids can modulate expression of proteins involved in copper trafficking.<sup>118</sup> Copper chaperone for superoxide dismutase (CCS), which is used as a marker for intracellular copper, shows decreased expression upon treatment with 3-hydroxyflavone and Cu(II) and increased expression when treated with quercetin and Cu(II). Compared to the other molecules studied, 3-hydroxyflavone is the one of the more lipophilic compounds. The lipophilicity paired with the binding ability of 3-hydroxyflavone maintains the important chemical properties of an ideal ionophore and should serve as inspiration for future investigations.

## 5. Future outlook

The health benefits of plant-based molecules are richly reported in the literature, with growing evidence associating plant-based diets with reduced risk of metabolic diseases, including cardiovascular disorders, metabolic syndrome, and type II diabetes.<sup>233,234</sup> Yet, much remains to be elucidated regarding the physicochemical properties of plant-based ingredients, how they differ from animal-based products, and the molecular mechanisms underlying their beneficial effects.<sup>233,235</sup> Even less explored is how their ionophoric and chelating capacities may be

linked to their mode of action. The surge in tools for visualizing metal trafficking in complex biological systems has shed new light on the importance of transition metal homeostasis and its perturbation in metabolic diseases.<sup>3,236,237</sup> It is timely to revisit the mechanisms by which plant-derived molecules elicit their function with respect to their interaction with metal homeostatic pathways. Leveraging these new tools should link structural insight to medicinal uses of plant-derived diets and components.

In this review, we brought to the forefront examples wherein metal-binding abilities are associated with beneficial effects on metabolic disorders. The majority of the highlighted studies focus on how the redox chemistry of the metals impact the pro- and antioxidant activity of these molecules. As new roles emerge for labile metal pools in cellular signaling, alternative pathways by which plant-based metal binders may function in disease alleviation should be explored beyond redox-focused interactions. Recent reports have already demonstrated this potential with synthetic or microbe-derived metal binders. Iron-binding siderophores<sup>238,239</sup> are gaining relevance not only in host-pathogen interactions in infection but also in the balance of the gut microbiota in healthy and dysmetabolic states<sup>82,240,241</sup> Tissue-targeted ionophores are finding unique therapeutic mechanisms in shifting metabolic balance.<sup>14,232,242-244</sup> It behooves researchers to consider such metal-trafficking functions when investigating metal associations of plant-derived therapies. These insights should find valuable intersections in determining how nutrition, diet, and natural product-derived therapies might address pressing challenges in metabolic diseases.

## Author contributions

V. J. L., S. E. J., and M. C. H. all contributed to the research and writing of the manuscript. V. J. L. and M. C. H. organized the manuscript. All authors have given approval to the final version of the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was supported by the National Institutes of Health (NIH MIRA 5R35GM133684 to M. C. H.), the National Science Foundation (NSF CAREER 2048265 to M. C. H.), and the UCSF Nutrition Obesity Research Center's Pilot & Feasibility Grant funded by the National Institutes of Health (P30DK098722 to M. C. H.). We also thank the Hartwell Foundation for their generous support for M. C. H. as a Hartwell Individual Biomedical Investigator, as well as the UC Davis CAMPOS Program and the University of California's Presidential Postdoctoral Fellowship for their support of M. C. H. as a CAMPOS Faculty Fellow and former UC President's Postdoctoral Fellow, respectively.

## References

- 1 L. A. Finney and V. T. O'Halloran, Transition metal speciation in the cell: Insights from the chemistry of metal ion receptors, *Science*, 2003, **300**, 931–936.
- 2 D. Buccella, M. H. Lim and J. R. Morrow, Metals in Biology: From Metallomics to Trafficking, *Inorg. Chem.*, 2019, **58**, 13505–13508.
- 3 C. J. Chang, Searching for harmony in transition-metal signaling, *Nat. Chem. Biol.*, 2015, **11**, 744–747.
- 4 M. Umair and M. Alfadhel, Genetic disorders associated with metal metabolism, *Cells*, 2019, **8**, 1–23.
- 5 S. Anagianni and K. Tuschl, Genetic Disorders of Manganese Metabolism, *Curr. Neurol. Neurosci. Rep.*, 2019, **19**, 33.
- 6 C. Gerosa, D. Fanni, T. Congiu, M. Piras, F. Cau, M. Moi and G. Faa, Liver pathology in Wilson's disease: From copper overload to cirrhosis, *J. Inorg. Biochem.*, 2019, **193**, 106–111.
- 7 S. Baldari, D. G. Rocco and G. Toiatta, Current biomedical use of copper chelation therapy, *Int. J. Mol. Sci.*, 2020, **21**, 1–20.
- 8 R. C. Moreno, A. Navas-Acien, E. Escolar, D. M. Nathan, J. Newman, J. F. Schmedtje, D. Diaz, G. A. Lamas and V. Fonseca, Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes, *J. Clin. Endocrinol. Metab.*, 2019, **104**, 2931–2941.
- 9 J. F. J. Bogie, M. Haidar, G. Kooij and J. J. A. Hendriks, Fatty acid metabolism in the progression and resolution of CNS disorders, *Adv. Drug Delivery Rev.*, 2020, **159**, 198–213.
- 10 J. Xu, H. Jiang, J. Li, K. K. Cheng, J. Dong and Z. Chen, <sup>1</sup>H NMR-based metabolomics investigation of copper-laden rat: A model of Wilson's disease, *PLoS One*, 2015, **10**, e0119654.
- 11 J. Chen, Y. Jiang, H. Shi, Y. Peng, X. Fan and C. Li, The molecular mechanisms of copper metabolism and its roles in human diseases, *Pflugers Archiv European Journal of Physiology*, 2020, **472**, 1415–1429.
- 12 L. Antonucci, C. Porcu, G. Iannucci, C. Balsano and B. Barbaro, Non-alcoholic fatty liver disease and nutritional implications: Special focus on copper, *Nutrients*, 2017, **9**, 1–12.
- 13 X. Ding, H. Xie and Y. J. Kang, The significance of copper chelators in clinical and experimental application, *J. Nutr. Biochem.*, 2011, **22**, 301–310.
- 14 V. Oliveri, Biomedical applications of copper ionophores, *Coordin. Chem. Rev.*, 2020, **422**, 213474.
- 15 A. Steinbrueck, A. C. Sedgwick, J. T. Brewster, K. C. Yan, Y. Shang, D. M. Knoll, G. I. Vargas-Zúñiga, X. P. He, H. Tian and J. L. Sessler, Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents, *Chem. Soc. Rev.*, 2020, **49**, 3726–3747.
- 16 M. E. Helsel, E. J. White, S. Z. A. Razvi, B. Alies and K. J. Franz, Chemical and functional properties of metal chelators that mobilize copper to elicit fungal killing of *Cryptococcus neoformans*, *Metallomics*, 2016, **9**, 69–81.
- 17 M. E. Helsel and K. J. Franz, Pharmacological activity of metal binding agents that alter copper bioavailability, *Dalton Trans.*, 2015, **44**, 8760–8770.
- 18 K. J. Franz, Clawing back: broadening the notion of metal chelators in medicine, *Curr. Opin. Chem. Biol.*, 2013, **17**, 143–149.
- 19 V. Seidel, Plant-derived chemicals: A source of inspiration for new drugs, *Plants*, 2020, **9**, 1–3.
- 20 F.-C. Wong, J. Xiao, S. Wang, K.-Y. Ee and T.-T. Chai, Advances on the antioxidant peptides from edible plant sources, *Trends Food Sci. Tech.*, 2020, **99**, 44–57.
- 21 T. Tsang, C. I. Davis and D. C. Brady, Copper biology, *Curr. Biol.*, 2021, **31**, R421–R427.
- 22 V. Abbate and R. Hider, Iron in biology, *Metallomics*, 2017, **9**, 1467–1469.
- 23 S. J. Forrester, D. S. Kikuchi, M. S. Hernandes, Q. Xu and K. K. Griendling, Reactive oxygen species in metabolic and inflammatory signaling, *Circ. Res.*, 2018, **122**, 877–902.
- 24 M. Behari and V. Pardasani, Genetics of Wilsons disease, *Parkinsonism Relat. Disord.*, 2010, **16**, 639–644.
- 25 A. Czlonkowska, T. Litwin, P. Dusek, P. Ferenci, S. Lutsenko, V. Medici, J. K. Rybakowski, K. H. Weiss and M. L. Schilsky, Wilson disease, *Nat. Rev. Dis. Primers*, 2018, **4**, 1–20.
- 26 H.-J. Zhong, P. Xiao, D. Lin, H.-M. Zhou and X.-X. He, Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia, *Int. J. Med. Sci.*, 2020, **17**, 1345–1350.
- 27 W. Hermann, Classification and differential diagnosis of Wilson's disease, *Annals of Translational Medicine*, *Ann. Transl. Med.*, 2019, **7**, S63.
- 28 K. I. Rodriguez-Castro, F. J. Hevia-Urrutia and G. C. Sturniolo, Wilson's disease: A review of what we have learned, *World J. Hepatol.*, 2015, **7**, 2859–2870.
- 29 R. J. Sokol, D. Twedt, J. M. McKim, M. W. Devereaux, F. M. Karrer, I. Kam, G. V. Steigman, M. R. Narkewicz, B. R. Bacon, R. S. Britton and B. A. Neuschwander-Tetri, Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis, *Gastroenterology*, 1994, **107**, 1788–1798.
- 30 H. Nagasaka, I. Inoue, A. Inui, H. Komatsu, T. Sogo, K. Murayama, T. Murakami, T. Yorifuji, K. Asayama, S. Katayama, S. Uemoto, K. Kobayashi, M. Takayanagi, T. Fujisawa and H. Tsukahara, Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: Hepatic manifestation in wilson disease as a consequence of augmented oxidative stress, *Pediatr. Res.*, 2006, **60**, 472–477.
- 31 M. C. Linder, Copper Homeostasis in Mammals, with Emphasis on Secretion and Excretion. A Review, *Int. J. Mol. Sci.*, 2020, **21**, 4932.
- 32 F. Tisato, C. Marzano, M. Porchia, M. Pellei and C. Santini, Copper in diseases and treatments, and copper-based anticancer strategies, *Med. Res. Rev.*, 2010, **30**, 708–749.
- 33 S. R. Davis and R. J. Cousins, Metallothionein expression in animals: A physiological perspective on function, *J. Nutr.*, 2000, **130**, 1085–1088.
- 34 G. J. Brewer, Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper

therapy in a wide variety of diseases, *Metallomics*, 2009, **1**, 199–206.

35 K. H. Weiss, D. N. Gotthardt, D. Klemm, U. Merle, D. Ferencioerster, M. Schaefer, P. Ferenci and W. Stremmel, Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease, *Gastroenterology*, 2011, **140**, 1189–1198.e1.

36 D. Denny-Brown and H. Porter, The Effect of BAL (2,3-Dimercaptopropanol) on Hepatolenticular Degeneration (Wilson's Disease), *N. Engl. J. Med.*, 1951, **245**, 917–925.

37 R. Purchase, The treatment of Wilson's disease, a rare genetic disorder of copper metabolism, *Sci. Progress*, 2013, **96**, 19–32.

38 J. M. Walshe, Penicillamine, a new oral therapy for Wilson's disease, *Am. J. Med.*, 1956, **21**, 487–495.

39 W. M. Weigert, H. Offermanns and P. S. Degussa, D-Penicillamine—Production and Properties, *Angew. Chem., Int. Ed. Engl.*, 1975, **14**, 330–336.

40 M. Pugliese, V. Biondi, E. Gugliandolo, P. Licata, A. F. Peritore, R. Crupi and A. Passantino, D-penicillamine: The state of the art in humans and in dogs from a pharmacological and regulatory perspective, *Antibiotics*, 2021, **10**, 1–15.

41 S. Khandpur, N. Jain, S. Singla, P. Chatterjee and M. Behari, D-penicillamine Induced Degenerative Dermopathy, *Indian J. Dermatol. Venereol.*, 2015, **60**, 406–409.

42 B. Sarkar, A. Sass-Kortsak, R. Clarke, S. H. Laurie and P. Wei, A Comparative Study of in vitro and in vivo Interaction of D-penicillamine and Triethylenetetramine with Copper, *J. Roy. Soc. Med.*, 1977, **70**, 13–18.

43 Z. Tümer and L. B. Møller, Menkes disease, *Eur. J. Hum. Genet.*, 2010, **18**, 511–518.

44 J. H. Menkes, M. Alter, G. K. Steigleder, D. R. Weakley and J. H. Sung, A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration, *Pediatrics*, 1962, **29**, 764–779.

45 S. G. Kaler, ATP7A-related copper transport diseases—emerging concepts and future trends, *Nat. Rev. Neurol.*, 2011, **7**, 15–29.

46 J. Kreuder, A. Otten, H. Fuder, Z. Tümer, T. Tønnesen, N. Horn and D. Dralle, Clinical and biochemical consequences of copper-histidine therapy in Menkes disease, *Eur. J. Pediatr.*, 1993, **152**, 828–832.

47 J. G. Millichap, Neonatal Diagnosis and Treatment of Menkes Disease, *Pediatr. Neurol. Briefs*, 2008, **22**, 16.

48 S. G. Kaler, Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment, *J. Trace Elem. Med. Biol.*, 2014, **28**, 427–430.

49 R. A. DeFronzo, E. Ferrannini, L. Groop, R. R. Henry, W. H. Herman, J. J. Holst, F. B. Hu, C. R. Kahn, I. Raz, G. I. Shulman, D. C. Simonson, M. A. Testa and R. Weiss, Type 2 diabetes mellitus, *Nat. Rev. Dis. Primers*, 2015, **1**, 1–23.

50 S. E. Kahn, R. L. Hull and K. M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes, *Nature*, 2006, **444**, 840–846.

51 A. Tanaka, H. Kaneto, T. Miyatsuka, K. Yamamoto, K. Yoshiuchi, Y. Yamasaki, I. Shimomura, T. A. Matsuoka and M. Matsuhisa, Role of copper ion in the pathogenesis of type 2 diabetes, *Endocr. J.*, 2009, **56**, 699–706.

52 J. A. Simcox and D. A. McClain, Iron and diabetes risk, *Cell Metab.*, 2013, **17**, 329–341.

53 A. Viktorínová, E. Tošerová, M. Križko and Z. Ďuračková, Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus, *Metabolism*, 2009, **58**, 1477–1482.

54 I. W. Dymock, J. Cassar, D. A. Pyke, W. G. Oakley and R. Williams, Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis, *Am. J. Med.*, 1972, **52**, 203–210.

55 S. N. Rajpathak, J. P. Crandall, J. Wylie-Rosett, G. C. Kabat, T. E. Rohan and F. B. Hu, The role of iron in type 2 diabetes in humans, *Biochim. Biophys. Acta, Gen. Subj.*, 2009, **1790**, 671–681.

56 W. Bao, Y. Rong, S. Rong and L. Liu, Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis, *BMC Med.*, 2012, **10**, 119.

57 R. C. Cooksey, D. Jones, S. Gabrielsen, J. Huang, J. A. Simcox, B. Luo, Y. Soesanto, H. Rienhoff, E. D. Abel and D. A. McClain, Dietary iron restriction or iron chelation protects from diabetes and loss of  $\beta$ -cell function in the obese (ob/ob lep/-) mouse, *Am. J. Physiol.: Endocrinol. Metab.*, 2010, **298**, 1236–1243.

58 H. F. Yan, Z. Y. Liu, Z. A. Guan and C. Guo, Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice, *Endocr. Connect.*, 2018, **7**, 604–616.

59 H. Yin, L. Xu and N. A. Porter, Free radical lipid peroxidation: Mechanisms and analysis, *Chem. Rev.*, 2011, **111**, 5944–5972.

60 K. Nowotny, T. Jung, A. Höhn, D. Weber and T. Grune, Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus, *Biomol.*, 2015, **5**, 194–222.

61 M. Nazari, K. W. Ho, N. Langley, K. M. Cha, R. Kodsi, M. Wang, D. R. Laybutt, K. Cheng, R. A. Stokes, M. M. Swarbrick and J. E. Gunton, Iron chelation increases beige fat differentiation and metabolic activity, preventing and treating obesity, *Sci. Rep.*, 2022, **12**, 1–11.

62 Z. Yao, Y. Gu, Q. Zhang, L. Liu, G. Meng, H. Wu, Y. Xia, X. Bao, H. Shi, S. Sun, X. Wang, M. Zhou, Q. Jia, Y. Wu, K. Song, W. Gao, C. Guo and K. Niu, Estimated daily quercetin intake and association with the prevalence of type 2 diabetes mellitus in Chinese adults, *Eur. J. Nutr.*, 2019, **58**, 819–830.

63 J. A. Vernarelli and J. D. Lambert, Flavonoid intake is inversely associated with obesity and C-reactive protein, a marker for inflammation, in US adults, *Nutr. Diabetes*, 2017, **7**, 22–24.

64 J. Peng, Q. Li, K. Li, L. Zhu, X. Lin, X. Lin, Q. Shen, G. Li and X. Xie, Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1, *J. Diabetes Res.*, 2017, **2017**, 3417306.

65 R. Dhanya, A. D. Arya, P. Nisha and P. Jayamurthy, Quercetin, a Lead Compound against Type 2 Diabetes Ameliorates Glucose Uptake via AMPK Pathway in Skeletal Muscle Cell Line, *Front. Pharmacol.*, 2017, **8**, 336.

66 H. Jiang, Y. Yamashita, A. Nakamura, K. Croft and H. Ashida, Quercetin and its metabolite isorhamnetin promote glucose uptake through different signalling pathways in myotubes, *Sci. Rep.*, 2019, **9**, 1–15.

67 D. Li, C. Jiang, G. Mei, Y. Zhao, L. Chen, J. Liu, Y. Tang, C. Gao and P. Yao, Quercetin alleviates ferroptosis of pancreatic  $\beta$  cells in type 2 diabetes, *Nutrients*, 2020, **12**, 1–15.

68 D. Hanahan and R. A. Weinberg, Hallmarks of cancer: The next generation, *Cell*, 2011, **144**, 646–674.

69 D. Ramchandani, M. Berisa, D. A. Tavarez, Z. Li, M. Miele, Y. Bai, S. B. Lee, Y. Ban, N. Dephoure, R. C. Hendrickson, S. M. Cloonan, D. Gao, J. R. Cross, L. T. Vahdat and V. Mittal, Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis, *Nat. Commun.*, 2021, **12**, 7311.

70 C. I. Davis, X. Gu, R. M. Kiefer, M. Ralle, T. P. Gade and D. C. Brady, Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation, *Metalomics*, 2020, **12**, 1995–2008.

71 R. Safi, E. R. Nelson, S. K. Chitneni, K. J. Franz, D. J. George, M. R. Zalutsky and D. P. McDonnell, Copper signaling axis as a target for prostate cancer therapeutics, *Cancer Res.*, 2014, **74**, 5819–5831.

72 M. C. Kew, Hepatic iron overload and hepatocellular carcinoma, *Liver Cancer*, 2014, **3**, 31–40.

73 S. Ishida, P. Andreux, C. Poitry-Yamate, J. Auwerx and D. Hanahan, Bioavailable copper modulates oxidative phosphorylation and growth of tumors, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 19507–19512.

74 S. Blockhuys, X. Zhang and P. Wittung-Stafshede, Single-cell tracking demonstrates copper chaperone Atox1 to be required for breast cancer cell migration, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 2014–2019.

75 T. Tsang, J. M. Posimo, A. A. Gudiel, M. Cicchini, D. M. Feldser and D. C. Brady, Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma, *Nat. Cell Biol.*, 2020, **22**, 412–424.

76 N. Chan, A. Willis, N. Kornhauser, M. Mward, S. B. Lee, E. Nackos, B. R. Seo, E. Chuang, T. Cigler, A. Moore, D. Donovan, M. V. Cobham, V. Fitzpatrick, S. Schneider, A. Wiener, J. Guillaume-Abraham, E. Aljom, R. Zelkowitz, J. D. Warren, M. E. Lane, C. Fischbach, V. Mittal and L. Vahdat, Influencing the tumor microenvironment: A Phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases, *Clin. Cancer Res.*, 2017, **23**, 666–676.

77 Y. L. Liu, C. L. Bager, N. Willumsen, D. Ramchandani, N. Kornhauser, L. Ling, M. Cobham, E. Andreopoulou, T. Cigler, A. Moore, D. LaPolla, V. Fitzpatrick, M. Ward, J. D. Warren, C. Fischbach, V. Mittal and L. T. Vahdat, Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer, *npj Breast Cancer*, 2021, **7**, 108.

78 Z. Yu, Z. Yu, Z. B. Chen, L. Yang, M. J. Ma, S. N. Lu, C. S. Wang, C. B. Teng and Y. Z. Nie, Zinc chelator TPEN induces pancreatic cancer cell death through causing oxidative stress and inhibiting cell autophagy, *J. Cell. Physiol.*, 2019, **234**, 20648–20661.

79 S. Amano, S. Kaino, S. Shinoda, H. Harima, T. Matsumoto, K. Fujisawa, T. Takami, N. Yamamoto, T. Yamasaki and I. Sakaida, Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox, *BMC Cancer*, 2020, **20**, 1–10.

80 T. Yamasaki, S. Terai and I. Sakaida, Deferoxamine for Advanced Hepatocellular Carcinoma, *N. Engl. J. Med.*, 2011, **365**, 576–578.

81 M. Whitnall, J. Howard, P. Ponka and D. R. Richardson, A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapy, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 14901–14906.

82 D. S. Kalinowski and D. R. Richardson, The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer, *Pharmacol. Rev.*, 2005, **57**, 547–583.

83 N. T. V. Le and D. R. Richardson, Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation, *Blood*, 2004, **104**, 2967–2975.

84 H. C. Hatcher, R. N. Singh, F. M. Torti and S. V. Torti, Synthetic and natural iron chelators: therapeutic potential and clinical use, *Future Med. Chem.*, 2009, **1**, 1643–1670.

85 Z. K. Pinnix, L. D. Miller, W. Wang, R. D'Agostino, T. Kute, M. C. Willingham, H. Hatcher, L. Tesfay, G. Sui, X. Di, S. V. Torti and F. M. Torti, Ferroportin and iron regulation in breast cancer progression and prognosis, *Sci. Transl. Med.*, 2010, **2**, 43ra56.

86 R. A. M. Brown, K. L. Richardson, T. D. Kabir, D. Trinder, R. Ganss and P. J. Leedman, Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology, *Front. Oncol.*, 2020, **10**, 476.

87 M. Fryknäs, X. Zhang, U. Bremberg, W. Senkowski, M. H. Olofsson, P. Brandt, I. Persson, P. D'Arcy, J. Gullbo, P. Nygren, L. K. Schughart, S. Linder and R. Larsson, Iron chelators target both proliferating and quiescent cancer cells, *Sci. Rep.-uk*, 2016, **6**, 38343.

88 J. L. Buss, B. T. Greene, J. Turner, F. M. Torti and S. V. Torti, Iron Chelators in Cancer Chemotherapy, *Curr. Top. Med. Chem.*, 2004, **4**, 1623–1635.

89 S. Srivastava, R. R. Somasagara, M. Hegde, M. Nishana, S. K. Tadi, M. Srivastava, B. Choudhary and S. C. Raghavan, Quercetin, a Natural Flavonoid Interacts with DNA, Arrests Cell Cycle and Causes Tumor Regression by Activating Mitochondrial Pathway of Apoptosis, *Sci. Rep.-uk*, 2016, **6**, 24049.

90 C. Y. Lan, S. Y. Chen, C. W. Kuo, C. C. Lu and G. C. Yen, Quercetin facilitates cell death and chemosensitivity

Published on 19 May 2023. Downloaded by University of California - Davis on 6/30/2023 8:28:03 PM.

through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells, *J. Food Drug Anal.*, 2019, **27**, 887–896.

91 S. Quideau, D. Deffieux, C. Douat-Casassus and L. Pouységu, Plant polyphenols: Chemical properties, biological activities, and synthesis, *Angew. Chem., Int. Ed.*, 2011, **50**, 586–621.

92 J. O. Chaves, M. C. de Souza, L. C. da Silva, D. Lachos-Perez, P. C. Torres-Mayanga, A. P. da, F. Machado, T. Forster-Carneiro, M. Vázquez-Espinosa, A. V. González-de-Peredo, G. F. Barbero and M. A. Rostagno, Extraction of Flavonoids From Natural Sources Using Modern Techniques, *Front. Chem.*, 2020, **8**, 507887.

93 Y. S. Tarahovsky, Y. A. Kim, E. A. Yagolnik and E. N. Muzaferov, Flavonoid-membrane interactions: Involvement of flavonoid-metal complexes in raft signaling, *Biochim. Biophys. Acta, Biomembr.*, 2014, **1838**, 1235–1246.

94 B. Dinda, M. Dinda, A. Roy and S. Dinda, Dietary plant flavonoids in prevention of obesity and diabetes, *Adv. Protein Chem. Struct. Biol.*, 2020, **120**, 159–235.

95 A. U. Khan, H. S. Dagur, M. Khan, N. Malik, M. Alam and M. Mushtaque, Therapeutic role of flavonoids and flavones in cancer prevention: Current trends and future perspectives, *Eur. J. Med. Chem. Rep.*, 2021, **3**, 100010.

96 S. Maiti, A. Nazmeen, N. Medda, R. Patra and T. K. Ghosh, Flavonoids green tea against oxidant stress and inflammation with related human diseases, *Clin. Nutr. Exp.*, 2019, **24**, 1–14.

97 M. H. Lim, Metal-associated amyloid-beta species in Alzheimer's disease, *Curr. Opin. Chem. Biol.*, 2012, **16**, 67–73.

98 X. He, H. M. Park, S.-J. Hyung, A. S. DeToma, C. Kim, B. T. Ruotolo and M. H. Lim, Exploring the reactivity of flavonoid compounds with metal-associated amyloid- $\beta$  species, *Dalton Trans.*, 2012, **41**, 6558.

99 S. Park, Y. Yi and M. H. Lim, Reactivity of Flavonoids Containing a Catechol or Pyrogallol Moiety with Metal-Free and Metal-Associated Amyloid- $\beta$ , *Bull. Korean Chem. Soc.*, 2021, **42**, 17–24.

100 G. Nam, M. Hong, J. Lee, H. J. Lee, Y. Ji, J. Kang, M.-H. Baik and M. H. Lim, Multiple reactivities of flavonoids towards pathological elements in Alzheimer's disease: structure-activity relationship, *Chem. Sci.*, 2020, **11**, 10243–10254.

101 C. Perez, Y. Tong and M. Guo, Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease, *Curr. Bioact. Compd.*, 2008, **4**, 150–158.

102 M. Guo, C. Perez, Y. Wei, E. Rapoza, G. Su, F. Bou-Abdallah and N. D. Chasteen, Iron-binding properties of plant phenolics and cranberry's bio-effects, *Dalton Trans.*, 2007, 4951–4961.

103 H. Yi, H. Peng, X. Wu, X. Xu, T. Kuang, J. Zhang, L. Du and G. Fan, The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence, *Oxid. Med. Cell. Longevity*, 2021, **2021**, 6678662.

104 X. Fang, W. Gao, Z. Yang, Z. Gao and H. Li, Dual Anti-Prooxidant Behaviors of Flavonoids Pertaining to Cu(II)-Catalyzed Tyrosine Nitration of the Insulin Receptor Kinase Domain in an Antidiabetic Study, *J. Agric. Food Chem.*, 2020, **68**, 6202–6211.

105 E. Cremonini, Z. Wang, A. Bettaieb, A. M. Adamo, E. Daveri, D. A. Mills, K. M. Kalanetra, F. G. Haj, S. Karakas and P. I. Oteiza, (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistance, *Redox Biol.*, 2018, **14**, 588–599.

106 L. Miao, H. Zhang, L. Yang, L. Chen, Y. Xie and J. Xiao, Flavonoids, *Antioxidants Effects in Health: The Bright and the Dark Side*, 2022, **58**, 353–374.

107 N. R. Perron and J. L. Brumaghim, A Review of the Antioxidant Mechanisms of Polyphenol Compounds Related to Iron Binding, *Cell Biochem. Biophys.*, 2009, **53**, 75–100.

108 M. Říha, J. Karličková, T. Filipský, K. Macáková, L. Rocha, P. Bovicelli, I. P. Silvestri, L. Saso, L. Jahodář, R. Hrdina and P. Mladěnka, In vitro evaluation of copper-chelating properties of flavonoids, *RSC Adv.*, 2014, **4**, 32628–32638.

109 M. D. Engelmann, R. Hutcheson and I. F. Cheng, Stability of ferric complexes with 3-hydroxyflavone (flavonol), 5,7-dihydroxyflavone (chrysin), and 3',4'-dihydroxyflavone, *J. Agric. Food Chem.*, 2005, **53**, 2953–2960.

110 M. C. Catapano, V. Tvrď, J. Karličková, T. Migkos, K. Valentová, V. Křen and P. Mladěnka, The stoichiometry of isoquercitrin complex with iron or copper is highly dependent on experimental conditions, *Nutrients*, 2017, **9**, 1–14.

111 K. T. J. Chen, M. Anantha, A. W. Y. Leung, J. A. Kulkarni, G. G. C. Militao, M. Wehbe, B. Sutherland, P. R. Cullis and M. B. Bally, Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use, *Drug Delivery Transl. Res.*, 2019, **10**, 202–215.

112 X. Tang, P. Tang and L. Liu, Molecular structure–Affinity relationship of Flavonoids in Lotus leaf (*Nelumbo nucifera* Gaertn.) on Binding to Human serum albumin and Bovine serum albumin by Spectroscopic Method, *Molecules*, 2017, **22**, 1036.

113 L. Mira, M. T. Fernandez, M. Santos, R. Rocha, M. H. Florêncio and K. R. Jennings, Interactions of flavonoids with iron and copper ions: A mechanism for their antioxidant activity, *Free Radical Res.*, 2002, **36**, 1199–1208.

114 S. A. Cherrak, N. Mokhtari-Soulimane, F. Berroukeche, B. Bensenane, A. Cherbonnel, H. Merzouk and M. Elhabiri, In vitro antioxidant versus metal ion chelating properties of flavonoids: A structure-activity investigation, *PLoS One*, 2016, **11**, 1–21.

115 M. Samsonowicz and E. Regulska, Spectroscopic study of molecular structure, antioxidant activity and biological effects of metal hydroxyflavonol complexes, *Spectrochim. Acta, Part A*, 2017, **173**, 757–771.

116 A. A. Ansari, DFT and  $^1\text{H}$  NMR molecular spectroscopic studies on biologically anti-oxidant active paramagnetic lanthanide(III)-chrysin complexes, *Main Group Chem.*, 2008, **7**, 43–56.

117 J. Karličková, K. Macáková, M. Říha, L. M. T. Pinheiro, T. Filipský, V. Horňasová, R. Hrdina and P. Mladěnka, Isoflavones reduce copper with minimal impact on iron in vitro, *Oxid. Med. Cell. Longevity*, 2015, 437381.

118 V. J. Lee and M. C. Heffern, Structure-activity assessment of flavonoids as modulators of copper transport, *Front. Chem.*, 2022, **10**, 1–15.

119 S. Azam, N. Hadi, N. U. Khan and S. M. Hadi, Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: Implications for anticancer properties, *Toxicol. In Vitro*, 2004, **18**, 555–561.

120 N. Kumar and N. Goel, Phenolic acids: Natural versatile molecules with promising therapeutic applications, *Bio-technology Rep.*, 2019, **24**, e00370.

121 S. M. Mandal, D. Chakraborty, S. Dey, S. M. Mandal, D. Chakraborty and S. Dey, Phenolic acids act as signaling molecules in plant- microbe symbioses Phenolic acids act as signaling molecules in plant-microbe symbioses, *Plant Signaling and Behavior*, 2017, **23**, 24, 359–368.

122 C. Srinivasulu, M. Ramgopal, G. Ramanjaneyulu, C. M. Anuradha and C. S. Kumar, Syringic acid (SA) – A Review of Its Occurrence, Biosynthesis, Pharmacological and Industrial Importance, *Biomed. Pharmacother.*, 2018, **108**, 547–557.

123 R. Masella, C. Santangelo, M. D'Archivio, G. LiVolti, C. Giovannini and F. Galvano, Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms, *Curr. Med. Chem.*, 2012, **19**, 2901–2917.

124 M. Kalinowska, E. Gołębiewska, G. Świderski, S. Męczyńska-Wielgosz, H. Lewandowska, A. Pietryczuk, A. Cudowski, A. Astel, R. Świsłocka, M. Samsonowicz, A. B. Złowodzka, W. Priebe and W. Lewandowski, Plant-derived and dietary hydroxybenzoic acids—a comprehensive study of structural, anti-/pro-oxidant, lipophilic, anti-microbial, and cytotoxic activity in MDA-MB-231 and MCF-7 cell lines, *Nutrients*, 2021, **13**, 3107.

125 B. H. J. Juurlink, H. J. Azouz, A. M. Z. Aldalati, B. M. H. Altinawi and P. Ganguly, Hydroxybenzoic acid isomers and the cardiovascular system, *Nutr. J.*, 2014, **13**, 1–10.

126 W. C. Chang, J. S. B. Wu, C. W. Chen, P. L. Kuo, H. M. Chien, Y. T. Wang and S. C. Shen, Protective effect of vanillic acid against hyperinsulinemia, hyperglycemia and hyperlipidemia via alleviating hepatic insulin resistance and inflammation in High-Fat Diet (HFD)-fed rats, *Nutrients*, 2015, **7**, 9946–9959.

127 M. Sreelekshmi and K. G. Raghu, Vanillic acid mitigates the impairments in glucose metabolism in HepG2 cells through BAD–GK interaction during hyperinsulinemia, *J. Biochem. Mol. Toxicol.*, 2021, **35**, 1–8.

128 S. Mohan, G. George and K. G. Raghu, Vanillic acid retains redox status in HepG2 cells during hyperinsulinemic shock using the mitochondrial pathway, *Food Biosci.*, 2021, **41**, 101016.

129 V. Ramachandran and B. Raja, Protective effects of syringic acid against acetaminophen-induced hepatic damage in albino rats, *J. Basic Clin. Physiol. Pharmacol.*, 2010, **21**, 369–386.

130 Y. Gao, R. Tian, H. Liu, H. Xue, R. Zhang, S. Han, L. Ji, W. Huang, J. Zhan and Y. You, Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease, *Crit. Rev. Food Sci. Nutr.*, 2021, 1–23.

131 M. E. Abdelmageed, G. S. G. Shehatou, G. M. Suddek and H. A. Salem, Protocatechuic acid improves hepatic insulin resistance and restores vascular oxidative status in type-2 diabetic rats, *Environ. Toxicol. Pharmacol.*, 2021, **83**, 103577.

132 A. Md, Alam, Anti-hypertensive Effect of Cereal Antioxidant Ferulic Acid and Its Mechanism of Action, *Front. Nutr.*, 2019, **6**, 121.

133 M. Srinivasan, A. R. Sudheer and V. P. Menon, Ferulic acid: Therapeutic potential through its antioxidant property, *J. Clin. Biochem. Nutr.*, 2007, **40**, 92–100.

134 J. Xu, J. Ge, X. He, Y. Sheng, S. Zheng, C. Zhang, W. Xu and K. Huang, Caffeic acid reduces body weight by regulating gut microbiota in diet-induced-obese mice, *J. Funct. Food*, 2020, **74**, 104061.

135 C. Yang, Q. Deng, J. Xu, X. Wang, C. Hu, H. Tang and F. Huang, Sinapic acid and resveratrol alleviate oxidative stress with modulation of gut microbiota in high-fat diet-fed rats, *Food Res. Int.*, 2019, **116**, 1202–1211.

136 J. Santana-Gálvez, L. Cisneros-Zevallos and D. Jacobo-Velázquez, Chlorogenic Acid: Recent Advances on Its Dual Role as a Food Additive and a Nutraceutical against Metabolic Syndrome, *Molecules*, 2017, **22**, 358.

137 A. Shi, T. Li, Y. Zheng, Y. Song, H. Wang, N. Wang, L. Dong and H. Shi, Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1, *Front. Pharmacol.*, 2021, **12**, 693048.

138 M. Abdollahi, S. M. Marandi, K. Ghaedi, Z. Safaeinejad, F. Kazeminasab, S. Shirkhani, M. H. Sanei, P. Rezvanian and M. H. Nasr-Esfahani, Insulin-Related Liver Pathways and the Therapeutic Effects of Aerobic Training, Green Coffee, and Chlorogenic Acid Supplementation in Prediabetic Mice, *Oxid. Med. Longevity*, 2022, **2022**, 1–14.

139 A. Mansour, M. R. Mohajeri-Tehrani, M. Samadi, M. Qorbani, S. Merat, H. Adibi, H. Poustchi and A. Hekmatdoost, Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-c, *Nutr. J.*, 2021, **20**, 1–11.

140 M. J. Hynes and M. O'Cinneannainn, The kinetics and mechanisms of reactions of iron(III) with caffeic acid, chlorogenic acid, sinapic acid, ferulic acid and naringin, *J. Inorg. Biochem.*, 2004, **98**, 1457–1464.

141 D. H. Truong, N. T. A. Nhung and D. Q. Dao, Iron ions chelation-based antioxidant potential vs. pro-oxidant risk of ferulic acid: A DFT study in aqueous phase, *Comput. Theor. Chem.*, 2020, **1185**, 112905.

142 K. Singh and A. Kumar, Kinetics of complex formation of Fe(III) with caffeic acid: Experimental and theoretical study, *Spectrochim. Acta, Part A*, 2019, **211**, 148–153.

143 M. Kalinowska, J. Sienkiewicz-Gromiuk, G. Świderski, A. Pietryczuk, A. Cudowski and W. Lewandowski, Zn(II) Complex of Plant Phenolic Chlorogenic Acid: Antioxidant,

Antimicrobial and Structural Studies, *Materials*, 2020, **13**, 3745.

144 G. Mazzone, On the Inhibition of Hydroxyl Radical Formation by Hydroxycinnamic Acids: The Case of Caffeic Acid as a Promising Chelating Ligand of a Ferrous Ion, *J. Phys. Chem. A*, 2019, **123**, 9560–9566.

145 I. M. Oke, L. M. Ramorobi, S. S. Masele, S. L. Bonnet, T. J. Makhafola, K. C. Eze, A. E. M. Norejaleel and C. I. Chukwuma, Vanillic acid-Zn(II) complex: a novel complex with antihyperglycaemic and anti-oxidative activity, *The, J. Pharm. Pharmacol.*, 2021, **73**, 1703–1714.

146 Y. Murata, M. Yoshida, N. Sakamoto, S. Morimoto, T. Watanabe and K. Namba, Iron uptake mediated by the plant-derived chelator nicotianamine in the small intestine, *J. Biol. Chem.*, 2021, **296**, 100195.

147 M. I. Hussain, Q. A. Syed, M. N. K. Khattak, B. Hafez, M. J. Reigosa and A. El-Keblawy, Natural product coumarins: biological and pharmacological perspectives, *Biologia*, 2019, **74**, 863–888.

148 E. K. Akkol, Y. Genç, B. Karpuz, E. Sobarzo-Sánchez and R. Capasso, Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer, *Cancers*, 2020, **12**, 1959.

149 A. Hiremathad, K. Chand and R. S. Keri, Development of coumarin–benzofuran hybrids as versatile multitargeted compounds for the treatment of Alzheimer's Disease, *Chem. Biol. Drug Des.*, 2018, **92**, 1497–1503.

150 J. C. Capra, M. P. Cunha, D. G. Machado, A. D. E. Zomkowski, B. G. Mendes, A. R. S. Santos, M. G. Pizzolatti and A. L. S. Rodrigues, Antidepressant-like effect of scopoletin, a coumarin isolated from *Polygala sabulosa* (Polygalaceae) in mice: Evidence for the involvement of monoaminergic systems, *Eur. J. Pharmacol.*, 2010, **643**, 232–238.

151 M. Y. Ali, S. Jannat, H. A. Jung, R. J. Choi, A. Roy and J. S. Choi, Anti-Alzheimer's disease potential of coumarins from *Angelica decursiva* and *Artemisia capillaris* and structure-activity analysis, *Asian Pac. J. Trop. Med.*, 2016, **9**, 103–111.

152 M. Y. Ali, H. A. Jung and J. S. Choi, Anti-diabetic and anti-Alzheimer's disease activities of *Angelica decursiva*, *Arch. Pharm. Res.*, 2015, **38**, 2216–2227.

153 M. N. Islam, H. A. Jung, H. S. Sohn, H. M. Kim and J. S. Choi, Potent  $\alpha$ -glucosidase and protein tyrosine phosphatase 1B inhibitors from *Artemisia capillaris*, *Arch. Pharmacal Res.*, 2013, **36**, 542–552.

154 H. Hussain, M. Nazir, M. Saleem, A. Al-Harrasi, Elizbit and I. R. Green, Fruitful decade of fungal metabolites as anti-diabetic agents from 2010 to 2019: emphasis on  $\alpha$ -glucosidase inhibitors, Springer Netherlands, vol. 20.

155 A. K. Tamrakar, C. K. Maurya and A. K. Rai, PTP1B inhibitors for type 2 diabetes treatment: A patent review (2011–2014), *Expert Opin. Ther. Pat.*, 2014, **24**, 1101–1115.

156 K. S. Kang, W. Lee, Y. Jung, J. H. Lee, S. Lee, D. W. Eom, Y. Jeon, H. H. Yoo, M. J. Jin, I. K. Song, W. J. Kim, J. Ham, H. J. Kim and S. N. Kim, Protective effect of esculetin on streptozotocin-induced diabetic renal damage in mice, *J. Agric. Food Chem.*, 2014, **62**, 2069–2076.

157 J. Wang, J. Lu, Y. Lan, H. Zhou, W. Li and M. Xiang, Total coumarins from *Urtica dentata* Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways, *J. Ethnopharmacol.*, 2013, **146**, 379–392.

158 N. Mergu, M. Kim and Y.-A. Son, A coumarin-derived Cu<sup>2+</sup>-fluorescent chemosensor and its direct application in aqueous media, *Spectrochim. Acta, Part A*, 2018, **188**, 571–580.

159 O. García-Beltrán, N. Mena, L. C. Friedrich, J. C. Netto-Ferreira, V. Vargas, F. H. Quina, M. T. Núñez and B. K. Cassels, Design and synthesis of a new coumarin-based “turn-on” fluorescent probe selective for Cu<sup>2+</sup>, *Tetrahedron Lett.*, 2012, **53**, 5280–5283.

160 P. Mladěnka, K. Macáková, L. Zatloukalová, Z. Řeháková, B. K. Singh, A. K. Prasad, V. S. Parmar, L. Jahodář, R. Hrdina and L. Sasová, In vitro interactions of coumarins with iron, *Biochimie*, 2010, **92**, 1108–1114.

161 P. Pecyna, J. Wargula, M. Murias and M. Kucinska, More than resveratrol: New insights into stilbene-based compounds, *Biomolecules*, 2020, **10**, 1–40.

162 A. P. Singh, R. Singh, S. S. Verma, V. Rai, C. H. Kaschula, P. Maiti and S. C. Gupta, Health benefits of resveratrol: Evidence from clinical studies, *Med. Res. Rev.*, 2019, **39**, 1851–1891.

163 Y. C. Chou, C. T. Ho and M. H. Pan, Stilbenes: Chemistry and Molecular Mechanisms of Anti-obesity, *Curr. Pharmacol. Rep.*, 2018, **4**, 202–209.

164 D. dos, S. Lacerda, P. Türck, B. G. de Lima-Seolin, R. Colombo, V. D. Ortiz, J. H. P. Bonetto, C. Campos-Carraro, S. E. Bianchi, A. Belló-Klein, V. L. Bassani and A. S. da Rosa Araujo, Pterostilbene reduces oxidative stress, prevents hypertrophy and preserves systolic function of right ventricle in cor pulmonale model, *Br. J. Pharmacol.*, 2017, **174**, 3302–3314.

165 D. Sunilkumar, G. Drishya, A. Chandrasekharan, S. K. Shaji, C. Bose, J. Jossart, J. J. P. Perry, N. Mishra, G. B. Kumar and B. G. Nair, Oxyresveratrol drives caspase-independent apoptosis-like cell death in MDA-MB-231 breast cancer cells through the induction of ROS, *Biochem. Pharmacol.*, 2020, **173**, 113724.

166 J. K. Hyo, W. L. Ki and J. L. Hyong, Protective effects of piceatannol against beta-amyloid-induced neuronal cell death, *Ann. N. Y. Acad. Sci.*, 2007, **1095**, 473–482.

167 H. Y. Tan, I. M. Y. Tse, E. T. S. Li and M. Wang, Oxyresveratrol supplementation to C57bl/6 mice fed with a high-fat diet ameliorates obesity-associated symptoms, *Nutrients*, 2017, **9**, 147.

168 J. H. Choi, N. J. Song, A. R. Lee, D. H. Lee, M. J. Seo, S. Kim, S. H. Chang, D. K. Yang, Y. J. Hwang, K. A. Hwang, T. S. Ha, U. J. Yun and K. W. Park, Oxyresveratrol increases energy expenditure through Foxo3a-mediated Ucp1 induction in high-fat-diet-induced obese mice, *Int. J. Mol. Sci.*, 2019, **20**, 26.

169 M. H. Pan, Y. C. Koh, T. L. Lee, B. Wang, W. K. Chen, K. Nagabhushanam and C. T. Ho, Resveratrol and Oxyresveratrol Activate Thermogenesis via Different Transcriptional

Coactivators in High-Fat Diet-Induced Obese Mice, *J. Agric. Food Chem.*, 2019, **67**, 13605–13616.

170 J. Kershaw and K. H. Kim, The Therapeutic Potential of Piceatannol, a Natural Stilbene, in Metabolic Diseases: A Review, *J. Med. Food*, 2017, **20**, 427–438.

171 M. Kitada, Y. Ogura, H. Maruki-Uchida, M. Sai, T. Suzuki, K. Kanasaki, Y. Hara, H. Seto, Y. Kuroshima, I. Monno and D. Koya, The effect of piceatannol from passion fruit (*Passiflora edulis*) seeds on metabolic health in humans, *Nutrients*, 2017, **9**, 1–17.

172 M. Pan, J. Wu, C. Ho and C. Lai, Antiobesity molecular mechanisms of action: Resveratrol and pterostilbene, *Bio-Factors*, 2018, **44**, 50–60.

173 T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis and U. K. Walle, High absorption but very low bioavailability of oral resveratrol in humans, *Drug Metab. Dispos.*, 2004, **32**, 1377–1382.

174 M. F. Ullah, A. Ahmad, H. Y. Khan, H. Zubair, F. H. Sarkar and S. M. Hadi, The Prooxidant Action of Dietary Antioxidants Leading to Cellular DNA Breakage and Anticancer Effects: Implications for Chemotherapeutic Action Against Cancer, *Cell Biochem. Biophys.*, 2013, **67**, 431–438.

175 L. F. Zheng, Q. Y. Wei, Y. J. Cai, J. G. Fang, B. Zhou, L. Yang and Z. L. Liu, DNA damage induced by resveratrol and its synthetic analogues in the presence of Cu (II) ions: Mechanism and structure-activity relationship, *Free Radical Biol. Med.*, 2006, **41**, 1807–1816.

176 P. A. Volkart, R. B. Gassen, B. M. Nogueira, B. N. Porto, J. E. Vargas and A. A. Souto, Antitumor activity of resveratrol is independent of Cu(II) complex formation in MCF-7 cell line, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 3238–3242.

177 Z. Li, X. Yang, S. Dong and X. Li, DNA breakage induced by piceatannol and copper(II): Mechanism and anticancer properties, *Oncol. Lett.*, 2012, **3**, 1087–1094.

178 V. Tamboli, A. Defant, I. Mancini and P. Tosi, A study of resveratrol-copper complexes by electrospray ionization mass spectrometry and density functional theory calculations, *Rapid Commun. Mass Spectrom.*, 2011, **25**, 526–532.

179 A. Granzotto and P. Zatta, Resveratrol and Alzheimer's disease: Message in a bottle on red wine and cognition, *Frontiers in Aging, Neuroscience*, 2014, **6**, 1–7.

180 B. Chiavarino, M. E. Crestoni, S. Fornarini, S. Taioli, I. Mancini and P. Tosi, Infrared spectroscopy of copper-resveratrol complexes: A joint experimental and theoretical study, *J. Chem. Phys.*, 2012, **137**, 024307.

181 A. Touré and X. Xueming, Flaxseed Lignans: Source, Bio-synthesis, Metabolism, Antioxidant Activity, Bio-Active Components, and Health Benefits, *Compr. Rev. Food Sci. Food Saf.*, 2010, **9**, 261–269.

182 A. L. Webb and M. L. McCullough, Dietary lignans: Potential role in cancer prevention, *Nutr. Cancer*, 2005, **51**, 117–131.

183 A. Senizza, G. Rocchetti, J. I. Mosele, V. Patrone, M. L. Callegari, L. Morelli and L. Lucini, Lignans and gut microbiota: An interplay revealing potential health implications, *Molecules*, 2020, **25**, 1–17.

184 J. Peterson, J. Dwyer, H. Adlercreutz, A. Scalbert, P. Jacques and M. L. McCullough, Dietary lignans: Physiology and potential for cardiovascular disease risk reduction, *Nutr. Rev.*, 2010, **68**, 571–603.

185 I. Zanella, G. Biasiotto, F. Holm and D. di Lorenzo, Cereal Lignans, Natural Compounds of Interest for Human Health?, *Nat. Prod. Commun.*, 2017, **12**, 139–146.

186 S. Soleymani, S. Habtemariam, R. Rahimi and S. M. Nabavi, The what and who of dietary lignans in human health: Special focus on prooxidant and antioxidant effects, *Trends Food Sci. Technol.*, 2020, **106**, 382–390.

187 C. Guang Li, C. Lin Ni, M. Yang, Y. Zhao Tang, Z. Li, Y. Juan Zhu, Z. Huan Jiang, B. Sun and C. Jun Li, Honokiol protects pancreatic  $\beta$  cell against high glucose and intermittent hypoxia-induced injury by activating Nrf2/ARE pathway in vitro and in vivo, *Biomed. Pharmacother.*, 2018, **97**, 1229–1237.

188 J. X. Liu, S. N. Shen, Q. Tong, Y. T. Wang and L. G. Lin, Honokiol protects hepatocytes from oxidative injury through mitochondrial deacetylase SIRT3, *Eur. J. Pharmacol.*, 2018, **834**, 176–187.

189 H. Y. Kim, J. K. Kim, J. H. Choi, J. Y. Jung, W. Y. Oh, D. C. Kim, H. S. Lee, Y. S. Kim, S. S. Kang, S. H. Lee and S. M. Lee, Hepatoprotective effect of pinoresinol on carbon tetrachloride-induced hepatic damage in mice, *J. Pharmacol. Sci.*, 2010, **112**, 105–112.

190 Y. W. Kim, Y. M. Kim, Y. M. Yang, T. H. Kim, S. J. Hwang, J. R. Lee, S. C. Kim and S. G. Kim, Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in *Saururus chinensis*, *Free Radical Biol. Med.*, 2010, **48**, 567–578.

191 J. Q. Ma, J. Ding, L. Zhang and C. M. Liu, Hepatoprotective properties of sesamin against CCl<sub>4</sub> induced oxidative stress-mediated apoptosis in mice via JNK pathway, *Food Chem. Toxicol.*, 2014, **64**, 41–48.

192 D. Lv, C. Q. Zhu and L. Liu, Sesamin ameliorates oxidative liver injury induced by carbon tetrachloride in rat, *Int. J. Clin. Exp. Pathol.*, 2015, **8**, 5733–5738.

193 C. Donoso-Fierro, J. Becerra, E. Bustos-Concha and M. Silva, Chelating and antioxidant activity of lignans from Chilean woods (Cupressaceae), *Holzforschung*, 2009, **63**, 559–563.

194 F. Fucassi, A. Heikal, L. I. Mikhalovska, G. Standen, I. U. Allan, V. S. Mikhalovsky and P. J. Cragg, Metal chelation by a plant lignan, secoisolariciresinol diglucoside, *J. Inclusion Phenom. Macroyclic Chem.*, 2014, **80**, 345–351.

195 F. Pivari, A. Mingione, C. Brasacchio and L. Soldati, Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment, *Nutrients*, 2019, **11**, 1837.

196 J. Zheng, J. Cheng, S. Zheng, Q. Feng and X. Xiao, Curcumin, A Polyphenolic Curcuminoid With Its Protective Effects and Molecular Mechanisms in Diabetes and Diabetic Cardiomyopathy, *Front. Pharmacol.*, 2018, **9**, 472.

197 F. Yuan, H. Dong, J. Gong, D. Wang, M. Hu, W. Huang, K. Fang, X. Qin, X. Qiu, X. Yang and F. Lu, A Systematic

Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases, *Adv. Nutr.*, 2019, **10**, 791–802.

198 J. Ibrahim, A. Y. Kabiru, T. Abdulrasheed-Adeleke, B. Lawal and A. H. Adewuyi, Antioxidant and hepatoprotective potentials of curcuminoid isolates from turmeric (*Curcuma longa*) rhizome on  $CCl_4$ -induced hepatic damage in Wistar rats, *J. Taibah Univ. Sci.*, 2020, **14**(1), 908–915.

199 C. P. V. Mary, S. Vijayakumar and R. Shankar, Metal chelating ability and antioxidant properties of Curcumin-metal complexes – A DFT approach, *J. Mol. Graphics Modell.*, 2018, **79**, 1–14.

200 T. Q. Hieu and D. T. T. Thao, Enhancing the Solubility of Curcumin Metal Complexes and Investigating Some of Their Biological Activities, *J. Chem.*, 2019, 8082195.

201 S. Prasad, D. Dubourdieu, A. Srivastava, P. Kumar and R. Lall, Metal-circumin complexes in therapeutics: An approach to enhance pharmacological effects of curcumin, *Int. J. Mol. Sci.*, 2021, **23**, 7094.

202 R. Yuan, Y. Li, S. Han, X. Chen, J. Chen, J. He, H. Gao, Y. Yang, S. Yang and Y. Yang, Fe-Circumin Nanozyme-Mediated Reactive Oxygen Species Scavenging and Anti-Inflammation for Acute Lung Injury, *ACS Central Sci.*, 2022, **8**, 10–21.

203 M. Rodriguez-Concepcion, J. Avalos, M. L. Bonet, A. Boronat, L. Gomez-Gomez, D. Hornero-Mendez, M. C. Limon, A. J. Meléndez-Martínez, B. Olmedilla-Alonso, A. Palou, J. Ribot, M. J. Rodrigo, L. Zacarias and C. Zhu, A global perspective on carotenoids: Metabolism, biotechnology, and benefits for nutrition and health, *Prog. Lipid Res.*, 2018, **70**, 62–93.

204 M. L. Bonet, J. A. Canas, J. Ribot and A. Palou, *Carotenoids in Nature, Biosynthesis, Regulation and Function*, 2016, vol. 79, pp. 359–375.

205 M. Zia-Ul-Haq, S. Dewanjee and M. Riaz, *Carotenoids: Structure and Function in the Human Body*, Springer, Switzerland, 1st edn, 2021.

206 K. Christensen, T. Lawler and J. Mares, Dietary carotenoids and non-alcoholic fatty liver disease among US adults, NHANES 2003–2014, *Nutrients*, 2019, **11**, 1–12.

207 Y. Cao, C. Wang, J. Liu, Z. M. Liu, W. H. Ling and Y. M. Chen, Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults, *Sci. Rep.*, 2015, **5**, 1–8.

208 L. I. Elvira-Torales, J. García-Alonso and M. J. Periago-Castón, Nutritional importance of carotenoids and their effect on liver health: A review, *Antioxidants*, 2019, **8**, 229.

209 M. Kobori, Y. Ni, Y. Takahashi, N. Watanabe, M. Sugiura, K. Ogawa, M. Nagashimada, S. Kaneko, S. Naito and T. Ota, B-Cryptoxanthin Alleviates Diet-Induced Nonalcoholic Steatohepatitis By Suppressing Inflammatory Gene Expression in Mice, *PLoS One*, 2014, **9**, 1–11.

210 A. Roohbakhsh, G. Karimi and M. Iranshahi, Carotenoids in the treatment of diabetes mellitus and its complications: A mechanistic review, *Biomed. Pharmacother.*, 2017, **91**, 31–42.

211 K. Jomova and M. Valko, Health protective effects of carotenoids and their interactions with other biological antioxidants, *Eur. J. Med. Chem.*, 2013, **70**, 102–110.

212 C. Uraipong and J. Zhao, In vitro digestion of rice bran proteins produces peptides with potent inhibitory effects on  $\alpha$ -glucosidase and angiotensin I converting enzyme, *J. Sci. Food Agric.*, 2018, **98**, 758–766.

213 T. J. Ashaolu, Soy bioactive peptides and the gut microbiota modulation, *Appl. Microbiol. Biotechnol.*, 2020, **104**, 9009–9017.

214 S. Chakrabarti, S. Guha and K. Majumder, Food-derived bioactive peptides in human health: Challenges and opportunities, *Nutrients*, 2018, **10**, 1–17.

215 M. Chalamaiah, W. Yu and J. Wu, Immunomodulatory and anticancer protein hydrolysates (peptides) from food proteins: A review, *Food Chem.*, 2018, **245**, 205–222.

216 S. Ramkisson, D. Dwarka, S. Venter and J. J. Mellem, In vitro anticancer and antioxidant potential of *Amaranthus cruentus* protein and its hydrolysates, *Food Sci. Technol.*, 2020, **40**, 634–639.

217 R. Jahanbani, S. M. Ghaffari, M. Salami, K. Vahdati, H. Sepehri, N. N. Sarvestani, N. Sheibani and A. A. Moosavi-Movahedi, Antioxidant and Anticancer Activities of Walnut (*Juglans regia* L.) Protein Hydrolysates Using Different Proteases, *Plant Food Hum. Nutr.*, 2016, **71**, 402–409.

218 S. Avilés-Gaxiola, J. León-Félix, Y. B. Jiménez-Nevárez, M. A. Angulo-Escalante, R. Ramos-Payán, J. Colado-Velázquez and J. B. Heredia, Antioxidant and anti-inflammatory properties of novel peptides from *Moringa oleifera* Lam. leaves, *S. Afr. J. Bot.*, 2021, **141**, 466–473.

219 N. M. Rodriguez-Martin, S. M.-D. la Paz, R. Toscano, E. Grao-Cruces, A. Villanueva, J. Pedroche, F. Millan and M. C. Millan-Linares, Hemp (*Cannabis sativa* L.) protein hydrolysates promote anti-inflammatory response in primary human monocytes, *Biomolecules*, 2020, **10**, 803.

220 S. Montserrat-de la Paz, N. M. Rodriguez-Martin, A. Villanueva, J. Pedroche, I. Cruz-Chamorro, F. Millan and M. C. Millan-Linares, Evaluation of Anti-Inflammatory and Atheroprotective Properties of Wheat Gluten Protein Hydrolysates in Primary Human Monocytes, *Foods*, 2020, **9**, 854.

221 C. Lammi, G. Aiello, G. Boschin and A. Arnoldi, Multi-functional peptides for the prevention of cardiovascular disease: A new concept in the area of bioactive food-derived peptides, *J. Funct. Foods*, 2019, **55**, 135–145.

222 J. G. C. Angeles, J. C. Villanueva, L. Y. C. Uy, S. M. Q. Mercado, M. C. L. Tsuchiya, J. P. Lado, M. R. N. Angelia, M. C. M. Bercansil-Clemencia, M. A. C. Estacio and M. A. O. Torio, Legumes as functional food for cardiovascular disease, *Appl. Sci.*, 2021, **11**, 1–39.

223 A. Jakubczyk, M. Karas, K. Rybczynska-Tkaczyk, E. Zielinska and D. Zielinski, Current trends of bioactive peptides - New sources and therapeutic effect, *Foods*, 2020, **9**, 846.

224 S. P. Patil, A. Goswami, K. Kalia and A. S. Kate, Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes, *Int. J. Pept. Res. Ther.*, 2020, **26**, 955–968.

225 A. F. de Medeiros, J. L. C. de Queiroz, B. L. L. Maciel and A. H. de A. Moraes, Hydrolyzed Proteins and Vegetable Peptides: Anti-Inflammatory Mechanisms in Obesity and Potential Therapeutic Targets, *Nutrients*, 2022, **14**, 690.

226 J. Jover, R. Bosque and J. Sales, A comparison of the binding affinity of the common amino acids with different metal cations, *Dalton Trans*, 2008, 6441–6453.

227 R. Esfandi, W. G. Willmore and A. Tsopmo, Peptidomic analysis of hydrolyzed oat bran proteins, and their in vitro antioxidant and metal chelating properties, *Food Chem.*, 2019, **279**, 49–57.

228 R. Hu, G. Chen and Y. Li, Production and characterization of antioxidative hydrolysates and peptides from corn gluten meal using papain, ficin, and bromelain, *Molecules*, 2020, **25**, 4091.

229 S. Kubglomsong, C. Theerakulkait, R. L. Reed, L. Yang, C. S. Maier and J. F. Stevens, Isolation and Identification of Tyrosinase-Inhibitory and Copper-Chelating Peptides from Hydrolyzed Rice-Bran-Derived Albumin, *J. Agric. Food Chem.*, 2018, **66**, 8346–8354.

230 T. Brown, Design thinking, *Harvard Bus. Rev.*, 2008, **86**, 84–92.

231 F. Dai, W. J. Yan, Y. T. Du, X. Z. Bao, X. Z. Li and B. Zhou, Structural basis, chemical driving forces and biological implications of flavones as Cu(II) ionophores, *Free Radical Biol. Med.*, 2017, **108**, 554–563.

232 V. Oliveri, Selective Targeting of Cancer Cells by Copper Ionophores: An Overview, *Front. Mol. Biosci.*, 2022, **9**, 1–14.

233 D. J. McClements and L. Grossmann, A brief review of the science behind the design of healthy and sustainable plant-based foods, *npj Sci. Food*, 2021, **5**, 17.

234 L. McGrath and M.-L. Fernandez, Plant-based diets and metabolic syndrome: Evaluating the influence of diet quality, *J. Agric Food Res.*, 2022, **9**, 100322.

235 C. G. Jose, R. H. Jacob and G. E. Gardner, Alternative cutting methods and dry aging reduce the shear force of hot boned beef striploin in *Bos indicus* cattle, *Meat Sci.*, 2020, **163**, 108036.

236 E. J. Ge, A. I. Bush, A. Casini, P. A. Cobine, J. R. Cross, G. M. DeNicola, Q. P. Dou, K. J. Franz, V. M. Gohil, S. Gupta, S. G. Kaler, S. Lutsenko, V. Mittal, M. J. Petris, R. Polishchuk, M. Ralle, M. L. Schilsky, N. K. Tonks, L. T. Vahdat, L. V. Aelst, D. Xi, P. Yuan, D. C. Brady and C. J. Chang, Connecting copper and cancer: from transition metal signalling to metalloplasia, *Nat. Rev. Cancer*, 2022, **22**, 102–113.

237 F. Qiu, L. Wu, G. Yang, C. Zhang, X. Liu, X. Sun, X. Chen and N. Wang, The role of iron metabolism in chronic diseases related to obesity, *Mol. Med.*, 2022, **28**, 130.

238 M. Saha, S. Sarkar, B. Sarkar, B. K. Sharma, S. Bhattacharjee and P. Tribedi, Microbial siderophores and their potential applications: a review, *Environ. Sci. Pollut. Res.*, 2016, **23**, 3984–3999.

239 A. Butler and R. M. Theisen, Iron(III)-siderophore coordination chemistry: Reactivity of marine siderophores, *Coordin. Chem. Rev.*, 2010, **254**, 288–296.

240 M. Ellermann and J. C. Arthur, Siderophore-mediated iron acquisition and modulation of host-bacterial interactions, *Free Radical Bio. Med.*, 2017, **105**, 68–78.

241 M. Nairz, D. Ferring-Appel, D. Casarrubea, T. Sonnweber, L. Viatte, A. Schroll, D. Haschka, F. C. Fang, M. W. Hentze, G. Weiss and B. Galy, Iron Regulatory Proteins Mediate Host Resistance to *Salmonella* Infection, *Cell Host Microbe*, 2015, **18**, 254–261.

242 T. A. Su, D. S. Shihadih, W. Cao, T. C. Detomaso, M. C. Heffern, S. Jia, A. Stahl and C. J. Chang, A Modular Ionophore Platform for Liver-Directed Copper Supplementation in Cells and Animals, *J. Am. Chem. Soc.*, 2018, **140**, 13764–13774.

243 P. M. Meggyesy, S. Masaldan, S. A. S. Clatworthy, I. Volitakis, D. J. Eyckens, K. Aston-Mourney and M. A. Cater, Copper Ionophores as Novel Antioesity Therapeutics, *Molecules*, 2020, **25**, 4957.

244 R. M. El-Lababidi and J. G. Rizk, Cefiderocol: A Siderophore Cephalosporin, *Ann. Pharmacother.*, 2020, **54**, 1215–1231.